

Prof. SALİH ŞANLIOĞLU

Personal Information

Office Phone: [+90 242 227 4401](tel:+902422274401) Extension: 3898

Office Phone: [+90 242 227 4401](tel:+902422274401) Extension: 3897

Email: sanlioglu@akdeniz.edu.tr

Web: <http://genetherapy.akdeniz.edu.tr>

Address: Akdeniz Üniversitesi Gen ve Hücre Tedavi Merkez Laboratuvar Binası 2. Kat Kampüs Antalya, 07058

International Researcher IDs

ORCID: 0000-0001-8379-5678

Publons / Web Of Science ResearcherID: F-9305-2016

Yoksis Researcher ID: 9665

Biography

A Short Biography of Salih Sanlioglu VMD, PhD:

Following his graduation from the School of Veterinary Medicine at Selcuk University in Turkiye, Salih Sanlioglu, VMD, PhD, pursued further studies at the Ohio State University College of Medicine, where he successfully earned both his Master's (1992) and PhD (1996) degrees in the field of Molecular Cell Biology and Genetics. After completing his postdoctoral training at the Human Gene Therapy Institute of the University of Pennsylvania in 1997 and an internal medicine research fellowship at the Gene Therapy Center of the University of Iowa in 2002, Dr. Sanlioglu joined the medical faculty at Akdeniz University in Antalya, Turkiye. There, he established the country's inaugural human gene and cell therapy facility, which can be accessed at <http://genetherapy.akdeniz.edu.tr>.

His initial research efforts in gene therapy were primarily focused on comprehending the mechanisms of Adeno Associated Virus (AAV) gene delivery into cells, resulting in publications featured on the covers of the Journal of Virology and Virology Journal. Subsequently, he made significant strides by using adenoviruses to transport genes encoding death ligands (TRAIL) for cancer treatment, garnering attention from journals such as Cancer Gene Therapy and Human Gene Therapy, among others.

Dr. Sanlioglu also demonstrated the feasibility of using adenovirus vectors to reprogram pancreatic islets for potential use in cell therapy studies for Type 1 diabetes. Given the gravity of diabetes as a disease suitable for gene therapy, he adopted the third generation of lentiviral vectors for delivering anti-diabetic genes to experimental subjects with obesity and diabetes. These vectors were chosen for their capacity to provide long-term gene expression without adverse effects. His groundbreaking research on gene therapy for diabetes appeared on the covers of Human Gene Therapy and Nature Gene Therapy Journal.

Furthermore, his recent research interests have extended to viral-mediated therapeutic gene delivery for preventing retinal degeneration in the diseased eye. Dr. Sanlioglu has also utilized gene editing technology, including CRISPR/Cas9, to rectify disease-causing mutations. He also holds an interest in the development of potent viral vector-based gene therapy vaccines aimed at combating pandemic infectious diseases like COVID-19.

Currently, Dr. Sanlioglu serves as the director of the Center for Gene and Cell Therapy and heads the newly established Department of Gene and Cell Therapy at Akdeniz University. His exemplary contributions continue to shape the field of gene therapy.

Education Information

Post Doctorate, University of Pennsylvania, College Of Medicine, United States Of America 1996 - 1997
Doctorate, Ohio State University, College Of Medicine, United States Of America 1992 - 1996
Postgraduate, Ohio State University, College Of Medicine, United States Of America 1990 - 1991
Undergraduate, Selcuk University, Faculty of Veterinary Medicine, Turkey 1983 - 1988

Dissertations

Doctorate, Ectopic Engrailed-2 expression through in vivo gene transfer and its consequence on cerebellar patterning., Ohio State University, College Of Medicine, Mcdb Graduate Program, 1996
Postgraduate, Molecular cloning and characterization of two novel human genes (RP1 and RP2) located upstream of complement C4A and C4B in the HLA Class III region., Ohio State University, Nationwide Children's Hospital, College Of Medicine , Mcdb Graduate Program, 1991

Research Areas

Medicine, Medical Biology, Internal Medicine Sciences, Medical Genetics, Health Sciences, Fundamental Medical Sciences

Academic Titles / Tasks

Professor, Akdeniz University, Faculty of Medicine, Temel Tıp Bilimleri, 2008 - Continues
Associate Professor, Akdeniz University, Faculty of Medicine, Temel Tıp Bilimleri, 2003 - 2008
Assistant Professor, Akdeniz University, Faculty of Medicine, Temel Tıp Bilimleri, 2002 - 2003
Researcher, The University of Iowa, College Of Medicine, Center For Gene And Cell Therapy, 1998 - 2002
Researcher, University of Pennsylvania, College Of Medicine, Institute For Human Gene Therapy, 1997 - 1998
Research Assistant, Ohio State University, College Of Medicine, MCDB Graduate Program, 1992 - 1996
Research Assistant, Ohio State University, College Of Medicine, MCDB Graduate Program, 1990 - 1992

Courses

Clinical Case Studies in Medical Genetics, Doctorate, 2020 - 2021
Cell and Gene Therapy, Doctorate, 2020 - 2021
Gene Therapy Vectors: Protocols, Postgraduate, 2020 - 2021
Animal Models of Human Genetic Diseases, Postgraduate, 2020 - 2021
Non-viral Gene Delivery Systems, Doctorate, 2020 - 2021
Clinical Applications of Gene and Cell Therapy, Doctorate, 2020 - 2021
Methods and Protocols in CRISPR Gene Editing, Postgraduate, 2020 - 2021
Principles of Gene Editing, Postgraduate, 2020 - 2021
Research in Gene and Cell Therapy, Doctorate, 2020 - 2021
Gene Therapy Vectors: Methods, Postgraduate, 2020 - 2021
Principles of Medical Genetics, Doctorate, 2020 - 2021
Gene Delivery Systems and Therapeutic Strategies, Doctorate, 2020 - 2021
Target Diseases in Gene and Cell Therapy, Doctorate, 2020 - 2021

Advising Theses

ŞANLIOĞLU S., Dejeneratif retinal gen tedavi çalışmaları için yeni deney hayvan modelinin oluşturulması Establishment of A new animal model for gene therapy studies of retinal degenerative diseases, Postgraduate, E.ÖZGECAN(Student), 2020

ŞANLIOĞLU S., İnsülin gen naklinin diyabetik hayvan modellerinde terapötik etkisinin belirlenmesi Therapeutic efficacy of insulin gene delivery in animal models of diabetes, Doctorate, Y.EMRE(Student), 2019

ŞANLIOĞLU S., Tip 1 diyabetik deneklerde lentivirus aracılı vazoaktif intestinal peptit gen naklinin terapötik etkinliğinin belirlenmesi Therapeutic efficacy of lentivirus mediated vasoactive intestinal peptide gene delivery in type 1 diabetes, Postgraduate, F.ERENDOR(Student), 2019

ŞANLIOĞLU S., Lentivirus aracılı glp-1 gen naklinin pankreasın beta hücreleri üzerindeki potansiyel proliferatif ve farklılaştırıcı etkisi Potential proliferative and differentiative effects of lentivirus mediated glp-1 gene therapy on pancreatic beta cells, Doctorate, M.HALE(Student), 2018

ŞANLIOĞLU S., 3. jenerasyon hiv tabanlı lentiviral vektörlerin in vivo uygulamalar için üretimi ve pürifikasyon yöntemlerinin optimizasyonu Optimization of production and purification methods of 3rd generation hiv based lentiviral vectors for in vivo applications, Postgraduate, H.BANU(Student), 2017

ŞANLIOĞLU S., Multiple myeloma hasta lenfositlerinde ölümcül ligand sentezinin önemi, Postgraduate, F.Zehra(Student), 2012

ŞANLIOĞLU S., Endometrium karsinomunda ölümcül trail ligand ve reseptör ekspresyon profilinin tümör evreleri ile ilişkilerinin belirlenmesi Determination of the relationship between trail ligand and receptor expression profile and tumor stages in endometrial carcinoma, Doctorate, Ç.AYDIN(Student), 2011

ŞANLIOĞLU S., Endometrium karsinomunda ölümcül trail ligand ve reseptör ekspresyon profilinin tümör evreleri ile ilişkilerinin belirlenmesi, Doctorate, Ç.Aydın(Student), 2011

ŞANLIOĞLU S., TRAIL (TNF ile ilişkili apoptozisi aktive eden ligand) ligand ve reseptör profillerinin romatoid artrit ile ilişkisi The relation between trail (TNF related apoptosis inducing ligand) ligand and receptor profile and rheumatoid arthritis, Doctorate, A.BİŞGİN(Student), 2010

ŞANLIOĞLU S., Birinci jenerasyon adenovirüs aracılı sistemik gen aktarımının deney hayvan modellerinde girişimsel olmayan yöntemlerle görüntülenmesi Noninvasive imaging of first generation adenovirus mediated systemic gene delivery in animal models, Postgraduate, S.KAHRAMAN(Student), 2009

ŞANLIOĞLU S., Tip 1 diyabet tedavisinde kullanılmak üzere adenovirüs aracılı TRAIL gen tedavi metodlarının geliştirilmesi ve etkinliklerinin diyabetik hayvan modellerinde test edilmesi Testing the treatment efficacy of adenovirus mediated TRAIL gene therapy approach in type 1 diabetic animal models, Doctorate, E.DİRİCE(Student), 2009

ŞANLIOĞLU S., Akciğer kanserinde rekombinant adenovirüs aracılı TRAIL transferinin potansiyel terapötik etkisi The potential therapeutical effect of recombinant adenovirus mediated TRAIL transfection in lung cancer, Postgraduate, Ç.AYDIN(Student), 2005

ŞANLIOĞLU S., İleri evre prostat kanseri hücre hatlarında TRAIL'a dirençlilik mekanizmalarının araştırılması Investigation of resistance mechanisms to TRAIL in advanced prostate cancer cell lines, Doctorate, A.DİLŞAD(Student), 2005

ŞANLIOĞLU S., Akciğer kanserinde rekombinant adenovirüs aracılı trail transferinin potansiyel terapötik etkisi, Postgraduate, Ç.Aydın(Student), 2005

ŞANLIOĞLU S., Karaçay B., İleri evre prostat kanseri hücre hatlarında TRAIL'a dirençlilik mekanizmalarının araştırılması, Doctorate, A.Dilşad(Student), 2005

ŞANLIOĞLU S., Prostat kanserlerinde PTEN ekspresyonunun western blot yöntemi ile gösterilmesi Determination of PTEN expression levels by western blotting in prostate cancer, Postgraduate, E.DİRİCE(Student), 2003

ŞANLIOĞLU S., Mesane kanserlerinde PTEN ekspresyonunun western-blot yöntemi ile gösterilmesi Detection of PTEN expression in bladder cancer with western-blot analysis, Postgraduate, D.YAŞAR(Student), 2003

ŞANLIOĞLU S., Mesane kanserlerinde pten ekspresyonunun western blot yöntemi ile gösterilmesi, Postgraduate, D.Yaşar(Student), 2003

Published journal articles indexed by SCI, SSCI, and AHCI

I. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a

- Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination**
Bisgin A., ŞANLIOĞLU A. D., Eksi Y. E., Griffith T. S., ŞANLIOĞLU S.
HUMAN GENE THERAPY, vol.32, no.11-12, pp.541-562, 2021 (SCI-Expanded)
- II. Genome engineering and disease modeling via programmable nucleases for insulin gene therapy; promises of CRISPR/Cas9 technology**
Eksi Y. E., ŞANLIOĞLU A. D., AKKAYA B., Ozturk B. E., ŞANLIOĞLU S.
WORLD JOURNAL OF STEM CELLS, vol.13, no.6, pp.485-502, 2021 (SCI-Expanded)
- III. A Chemical Agent Induced Retinal Degenerative Disease Animal Model for Gene Therapy**
Sahin E. O., AKKAYA B., BİLGİN A. B., Ceylaner S., ŞANLIOĞLU S.
MOLECULAR THERAPY, vol.29, no.4, pp.273-274, 2021 (SCI-Expanded)
- IV. Combined Efficacy of Insulin and Anti-Inflammatory Gene Therapies for Type 1 Diabetes Mellitus**
ERENDOR F., Eksi Y. E., Sahin E. O., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
MOLECULAR THERAPY, vol.29, no.4, pp.239-240, 2021 (SCI-Expanded)
- V. Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation**
ERENDOR F., Sahin E. O., ŞANLIOĞLU A. D., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
GENE THERAPY, vol.28, no.3-4, pp.130-141, 2021 (SCI-Expanded)
- VI. Construction of Vasoactive Intestinal Peptide Encoding Lentiviral Gene Therapy Vector for Retinal Dystrophies**
AKKAYA B., Sahin E. O., Ceylaner S., BİLGİN A. B., ŞANLIOĞLU S.
MOLECULAR THERAPY, vol.29, no.4, pp.266, 2021 (SCI-Expanded)
- VII. Lentivirus Mediated Pancreatic Beta-Cell-Specific Insulin Gene Therapy for STZ-Induced Diabetes**
ERENDOR F., Emre Y., Ozgecan E., Blaci M. K., Griffith T. S., ŞANLIOĞLU S.
MOLECULAR THERAPY, vol.29, no.1, pp.149-161, 2021 (SCI-Expanded)
- VIII. High-grade purification of third-generation HIV-based lentiviral vectors by anion exchange chromatography for experimental gene and stem cell therapy applications. METHODS IN**
Olgun H. B., TAŞYÜREK M. H., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
MOLECULAR BIOLOGY, vol.1879, pp.347-365, 2019 (SCI-Expanded)
- IX. High titer production of HIV-based Lentiviral Vectors in roller bottles for Gene and Cell therapy METHODS IN**
OLGUN H. B., TAŞYÜREK M. H., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
MOLECULAR BIOLOGY, vol.1879, pp.323-345, 2019 (SCI-Expanded)
- X. Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes**
Tasyurek H. M., Altunbas H. A., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
HUMAN GENE THERAPY, vol.29, no.7, pp.802-815, 2018 (SCI-Expanded)
- XI. HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes**
Tasyurek H. M., Eksi Y. E., ŞANLIOĞLU A. D., Altunbas H. A., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
GENE THERAPY, vol.25, no.4, pp.269-283, 2018 (SCI-Expanded)
- XII. FDA Onaylı İlk Onkolitik Viral Terapi Ajanı Talimogene Laherparepvec'in (IMLYGIC) Öyküsü**
EKŞİ Y. E., ŞANLIOĞLU S.
Turkish Journal of Medical Sciences, vol.1, no.2, pp.80-89, 2016 (SCI-Expanded)
- XIII. Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors**
Timur M., Cort A., Ozdemir E., SARIKCIOGLU S., ŞANLIOĞLU S., ŞANLIOĞLU A. D., Ozben T.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.15, no.1, pp.99-106, 2015 (SCI-Expanded)
- XIV. Incretins: Their physiology and application in the treatment of diabetes mellitus**
TASYUREK H. M., Altunbas H. A., BALCI M. K., ŞANLIOĞLU S.
DIABETES-METABOLISM RESEARCH AND REVIEWS, vol.30, no.5, pp.354-371, 2014 (SCI-Expanded)
- XV. Construction and Evaluation of Lentiviral Vectors Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**

- BALCI M. K., Tasyurek H. M., Altunbas H. A., Balik O., Eksi Y. E., ŞANLIOĞLU S.
ENDOCRINE REVIEWS, vol.35, no.3, 2014 (SCI-Expanded)
- XVI. **Inkretin Tabanlı Tedavi Stratejilerinde Komplikasyon Kaygıları ve Senaryoları**
ŞANLIOĞLU S.
Turkish Journal of Medical Sciences, vol.2, no.1, pp.19-24, 2014 (SCI-Expanded)
- XVII. **GLP-1-mediated gene therapy approaches for diabetes treatment**
Tasyurek M. H., Altunbas H. A., CANATAN H., Griffith T. S., ŞANLIOĞLU S.
EXPERT REVIEWS IN MOLECULAR MEDICINE, vol.16, 2014 (SCI-Expanded)
- XVIII. **Downregulation of Vasoactive Intestinal Peptide Expression in Type 2 Diabetes**
Hapil F. Z., TASYUREK H., GUZEL N., SANLIOGLU A. D., Balci M. K., Sanlioglu S.
DIABETES, vol.62, 2013 (SCI-Expanded)
- XIX. **Clinical utility of insulin and insulin analogs**
ŞANLIOĞLU A. D., Altunbas H. A., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
ISLETS, vol.5, no.2, pp.67-78, 2013 (SCI-Expanded)
- XX. **Therapeutic potential of VIP vs PACAP in diabetes**
ŞANLIOĞLU A. D., Karacay B., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol.49, no.3, 2012 (SCI-Expanded)
- XXI. **Insulin gene therapy from design to beta cell generation**
ŞANLIOĞLU A. D., Altunbas H. A., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
EXPERT REVIEWS IN MOLECULAR MEDICINE, vol.14, 2012 (SCI-Expanded)
- XXII. **Tip 1 diyabetli hastalarda insulin tedavisinde ve insulin gen terapisinde güncel gelişmeler**
ŞANLIOĞLU S.
Turkish Journal of Medical Sciences, vol.1, no.5, pp.1-5, 2012 (SCI-Expanded)
- XXIII. **Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer**
BISGIN A., KARGI A., YALCIN A. D., AYDIN C., EKINCI D., SAVAS B., ŞANLIOĞLU S.
BMC CANCER, vol.12, 2012 (SCI-Expanded)
- XXIV. **TRAIL and DcR1 Expressions Are Differentially Regulated in the Pancreatic Islets of STZ- versus CY- Applied NOD Mice**
Dirice E., Kahraman S., ELPEK G. Ö., Aydin C., BALCI M. K., Omer A., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
EXPERIMENTAL DIABETES RESEARCH, vol.2011, 2011 (SCI-Expanded)
- XXV. **Tracing of islet graft survival by way of in vivo fluorescence imaging**
Kahraman S., Dirice E., Hapil F. Z., ERTOSUN M. G., ÖZTÜRK S., Griffith T. S., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
DIABETES-METABOLISM RESEARCH AND REVIEWS, vol.27, no.6, pp.575-583, 2011 (SCI-Expanded)
- XXVI. **CLINICAL SIGNIFICANCE OF TRAIL AND TRAIL RECEPTORS IN PATIENTS WITH HEAD AND NECK CANCER**
Yoldas B., Ozer C., Ozen O., Canpolat T., Dogan I., Griffith T. S., ŞANLIOĞLU S., Ozluoglu L. N.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, vol.33, no.9, pp.1278-1284, 2011 (SCI-Expanded)
- XXVII. **NF-kappa B targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL**
AYDIN C., ŞANLIOĞLU A. D., BISGIN A., Yoldas B., DERTSİZ L., Karacay B., Griffith T. S., ŞANLIOĞLU S.
BMC CANCER, vol.10, 2010 (SCI-Expanded)
- XXVIII. **TRAIL Death Receptor-4, Decoy Receptor-1 and Decoy Receptor-2 Expression on CD8(+) T Cells Correlate with the Disease Severity in Patients with Rheumatoid Arthritis**
BISGIN A., TERZIOGLU E., AYDIN C., Yoldas B., YAZISIZ V., BALCI N., Bagci H., Gorczynski R. M., AKDIS C. A., ŞANLIOĞLU S.
BMC MUSCULOSKELETAL DISORDERS, vol.11, 2010 (SCI-Expanded)
- XXIX. **In Vivo Fluorescence Imaging is Well-Suited for the Monitoring of Adenovirus Directed Transgene Expression in Living Organisms**
KAHRAMAN S., DIRICE E., ŞANLIOĞLU A. D., Yoldas B., Bagci H., ERKILIÇ M., Griffith T. S., ŞANLIOĞLU S.

- MOLECULAR IMAGING AND BIOLOGY, vol.12, no.3, pp.278-285, 2010 (SCI-Expanded)
- XXX. **Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis**
Kutlu Ö., Akkaya E., KÖKSAL İ. T., Bassorgun I. C., Ciftcioglu M. A., ŞANLIOĞLU S., Kukul E.
INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.42, no.2, pp.393-399, 2010 (SCI-Expanded)
- XXXI. **Effects of Androgen Ablation Therapy in TRAIL Death Ligand and Its Receptors Expression in Advanced Prostate Cancer**
KÖKSAL İ. T., ŞANLIOĞLU A. D., Kutlu Ö., ŞANLIOĞLU S.
UROLOGIA INTERNATIONALIS, vol.84, no.4, pp.445-451, 2010 (SCI-Expanded)
- XXXII. **Gen Tedavisinin Dünü Bugünü ve Yarını**
ŞANLIOĞLU S.
Turkish Journal of Medical Sciences, vol.42, no.505, pp.38-43, 2009 (SCI-Expanded)
- XXXIII. **Adenovirus-Mediated TRAIL Gene (Ad5hTRAIL) Delivery into Pancreatic Islets Prolongs Normoglycemia in Streptozotocin-Induced Diabetic Rats**
DIRICE E., ŞANLIOĞLU A. D., KAHRAMAN S., ÖZTÜRK S., BALCI M. K., Omer A., Griffith T. S., ŞANLIOĞLU S.
HUMAN GENE THERAPY, vol.20, no.10, pp.1177-1189, 2009 (SCI-Expanded)
- XXXIV. **CTLA-4 gene polymorphism of exon 1(+49 A/G) in Turkish systemic lupus erythematosus patients**
Ulker M., YAZISIZ V., Sallakci N., Avci A. B., ŞANLIOĞLU S., Yegin O., Terzioglu E.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS, vol.36, no.4, pp.245-250, 2009 (SCI-Expanded)
- XXXV. **HIGHLIGHTS IN THE MOLECULAR PATHOGENESIS OF TYPE 1 DIABETES**
Kahraman S., Dirice E., BALCI M. K., Omer A., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
IUBMB LIFE, vol.61, no.3, pp.324-325, 2009 (SCI-Expanded)
- XXXVI. **IN VIVO FLUORESCENT IMAGING OF ALLOGENEIC AND XENOGENEIC ISLET GRAFTS FOLLOWING TRANSPLANTATION**
KAHRAMAN S., DIRICE E., ŞANLIOĞLU A. D., BALCI M. K., Omer A., ŞANLIOĞLU S.
IUBMB LIFE, vol.61, no.3, pp.378-379, 2009 (SCI-Expanded)
- XXXVII. **MOLECULAR PROFILE OF TRAIL AND ITS RECEPTOR EXPRESSION ON PANCREAS OF STREPTOZOTOCIN-INDUCED DIABETES IN NOD MICE**
Kahraman S., Drice E., BALCI M. K., Omer A., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
IUBMB LIFE, vol.61, no.3, pp.324, 2009 (SCI-Expanded)
- XXXVIII. **GENETICALLY ENGINEERED PANCREATIC ISLETS EXPRESSING TRAIL EXTENDS SURVIVAL OF TRANSPLANTED PANCREATIC ISLETS IN STZ-INDUCED DIABETIC RATS**
DIRICE E., ŞANLIOĞLU A. D., KAHRAMAN S., Omer A., BALCI M. K., ŞANLIOĞLU S.
IUBMB LIFE, vol.61, no.3, pp.341, 2009 (SCI-Expanded)
- XXXIX. **High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients**
ŞANLIOĞLU A. D., Dirice E., Elpek O., Korcum A. F., OZDOGAN M., SÜLEYMANLAR İ., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
PANCREAS, vol.38, no.2, pp.154-160, 2009 (SCI-Expanded)
- XL. **EXPRESSION PROFILES OF TRAIL LIGAND AND RECEPTORS IN ENDOMETRIAL CARCINOMA**
Aydin C., Sanlioglu A. D., ŞANLIOĞLU S.
IUBMB LIFE, vol.61, no.3, pp.333, 2009 (SCI-Expanded)
- XLI. **CELL AND GENE THERAPY APPROACHES TO PROLONG ISLET-GRAFT SURVIVAL IN PATIENTS WITH TYPE 1 DIABETES**
DIRICE E., ŞANLIOĞLU A. D., KAHRAMAN S., BALCI M. K., Omer A., ŞANLIOĞLU S.
IUBMB LIFE, vol.61, no.3, pp.314, 2009 (SCI-Expanded)
- XLII. **Radiotherapy-induced decreases in substance P levels may potentiate melanoma growth**
Korcum A. F., ŞANLIOĞLU S., Aksu G., TUNÇEL N., ERİN N.
MOLECULAR MEDICINE REPORTS, vol.2, no.2, pp.319-326, 2009 (SCI-Expanded)
- XLIII. **MOLECULAR CHARACTERIZATION OF TRAIL LIGAND AND RECEPTOR EXPRESSIONS IN CYCLOPHOSPHAMIDE-INDUCED TYPE 1 DIABETES IN NOD MICE**
DIRICE E., KAHRAMAN S., BALCI M. K., Omer A., ŞANLIOĞLU S., ŞANLIOĞLU A. D.

- IUBMB LIFE, vol.61, no.3, pp.325, 2009 (SCI-Expanded)
- XLIV. **MOLECULAR PROFILE OF TUMOR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND (TRAIL) AND ITS RECEPTORS ON T CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS**
BİSGİN A., YAZISIZ V., Terzioglu E., ŞANLIOĞLU S.
IUBMB LIFE, vol.61, no.3, pp.327, 2009 (SCI-Expanded)
- XLV. **Molecular mechanisms of death ligand-mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes**
ŞANLIOĞLU A. D., Griffith T. S., Omer A., Dirice E., SARI R., Altunbas H. A., BALCI M. K., ŞANLIOĞLU S.
JOURNAL OF CELLULAR BIOCHEMISTRY, vol.104, no.3, pp.710-720, 2008 (SCI-Expanded)
- XLVI. **High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas**
ŞANLIOĞLU A. D., DIRICE E., ELPEK O., Korcum A. F., BALCI M. K., Omer A., Griffith T. S., ŞANLIOĞLU S.
PANCREAS, vol.36, no.4, pp.385-393, 2008 (SCI-Expanded)
- XLVII. **Differential alteration of TRAIL and its receptor expression profiles in patients with pancreatic ductal adenocarcinoma**
Sanlioglu A. D., DİRİCE E., Elpek O., Korcum A. F., Balci M. K., OMER A., GRIFFITH T. S., Sanlioglu S.
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (SCI-Expanded)
- XLVIII. **Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma**
KÖKSAL İ. T., ŞANLIOĞLU A. D., Karacay B., Griffith T. S., ŞANLIOĞLU S.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.26, no.2, pp.158-165, 2008 (SCI-Expanded)
- XLIX. **DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells**
Sanlioglu A. D., KARACAY B., KOKSAL I. T., GRIFFITH T. S., Sanlioglu S.
CANCER GENE THERAPY, vol.14, no.12, pp.976-984, 2007 (SCI-Expanded)
- L. **Corneal protein nitration in experimental uveitis**
Aslan M., Yucel I., Ciftcioglu A., Savas B., Akar Y., Yucel G., Sanlioglu S.
EXPERIMENTAL BIOLOGY AND MEDICINE, vol.232, no.10, pp.1308-1313, 2007 (SCI-Expanded)
- LI. **Trail death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma**
SANLIOĞLU A. D., KORCUM A. F., Pestereli E., Erdogan G., Karaveli S., SAVAS B., GRIFFITH T. S., Sanlioglu S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.69, no.3, pp.716-723, 2007 (SCI-Expanded)
- LII. **Testing the efficacy of substance P fragments as antitumor agents**
Erin N., Korcum A. F., Simsek E., Aydemir E., Sanlioglu S.
DRUGS OF THE FUTURE, vol.32, pp.58, 2007 (SCI-Expanded)
- LIII. **Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis**
Terzioglu E., Bisgin A., Sanlioglu A. D., Ulker M., Yazisiz V., Tuzuner S., Sanlioglu S.
RHEUMATOLOGY, vol.46, no.5, pp.783-789, 2007 (SCI-Expanded)
- LIV. **Differential expression of TRAIL and its receptors in benign and malignant prostate tissues**
Sanlioglu A. D., Koksal I. T., Ciftcioglu A., Baykara M., Lüleci G., Sanlioglu S.
JOURNAL OF UROLOGY, vol.177, no.1, pp.359-364, 2007 (SCI-Expanded)
- LV. **Pleiotropic functions of TNF-alpha determine distinct IKK beta-dependent hepatocellular fates in response to LPS**
DAJANI R., Sanlioglu S., ZHANG Y., LI Q., MONICK M. M., LAZARTIGUES E., EGGLESTON T., DAVISSON R. L., HUNNINGHAKE G. W., ENGELHARDT J. F.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol.292, no.1, 2007 (SCI-Expanded)

- LVI. **Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells**
AYDIN C., SANLIOGLU A. D., KARACAY B., Ozbilim G., Dertsiz L., Ozbudak O., AKDIS C. A., Sanlioglu S.
HUMAN GENE THERAPY, vol.18, no.1, pp.39-50, 2007 (SCI-Expanded)
- LVII. **Adenovirus-mediated IKK beta KA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis**
SANLIOGLU A. D., KOKSAL I., KARACAY B., Baykara M., LULECI G., Sanlioglu S.
CANCER GENE THERAPY, vol.13, no.1, pp.21-31, 2006 (SCI-Expanded)
- LVIII. **Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells**
Şanlıoğlu A. D., Dirice E., Aydın Ç., Erin N., Koksoy S., Şanlıoğlu S.
BMC CANCER, vol.5, 2005 (SCI-Expanded)
- LIX. **The effect of cetirizine on IFN-gamma and IL-10 production in children with allergic rhinitis**
UGUZ A., Sanlioglu S., YUZBEY S., COSKUN M., Yegin O.
TURKISH JOURNAL OF PEDIATRICS, vol.47, no.2, pp.111-115, 2005 (SCI-Expanded)
- LX. **Differential PTEN protein expression profiles in superficial versus invasive bladder cancers**
KOKSAL I., YASAR D., DIRICE E., USTA M. F., Karauzum S., Lüleci G., Baykara M., Sanlioglu S.
UROLOGIA INTERNATIONALIS, vol.75, no.2, pp.102-106, 2005 (SCI-Expanded)
- LXI. **Inhibition of the NF-kappa B pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells**
Karaçay B., Sanlioglu S., GRIFFITH T., SANDLER A., BONTHIUS D.
CANCER GENE THERAPY, vol.11, no.10, pp.681-690, 2004 (SCI-Expanded)
- LXII. **Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction**
SANLIOGLU A. D., KARACAY B., BENSON P., ENGELHARDT J., Sanlioglu S.
VIRUS RESEARCH, vol.104, no.1, pp.51-59, 2004 (SCI-Expanded)
- LXIII. **The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma**
Koksal I., DIRICE E., YASAR D., Sanlioglu A. D., Ciftcioglu A., Gulkesen K. H., Ozes N., Baykara M., Luleci G., Sanlioglu S.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.22, no.4, pp.307-312, 2004 (SCI-Expanded)
- LXIV. **Fundamental principals of tumor necrosis factor-alpha gene therapy approach and implications for patients with lung carcinoma**
Sanlioglu A. D., AYDIN C., BOZCUK H. S., Terzioglu E., Sanlioglu S.
LUNG CANCER, vol.44, no.2, pp.199-211, 2004 (SCI-Expanded)
- LXV. **Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma**
ŞANLIOĞLU A. D., KÖKSAL İ. T., BAYKARA M., LULECI G., KARACAY B., ŞANLIOĞLU S.
GENE THERAPY AND MOLECULAR BIOLOGY, no.7, pp.113-133, 2003 (SSCI)
- LXVI. **Genetic redox preconditioning differentially modulates AP-1 and NF kappa B responses following cardiac ischemia/reperfusion injury and protects against necrosis and apoptosis**
YANG J., MARDEN J., FAN C., Sanlioglu S., WEISS R., RITCHIE T., DAVISSON R., ENGELHARDT J.
MOLECULAR THERAPY, vol.7, no.3, pp.341-353, 2003 (SCI-Expanded)
- LXVII. **First-generation adenovirus vectors shorten survival time in a murine model of sepsis**
DOERSCHUG K., Sanlioglu S., FLAHERTY D., WILSON R., YAROVINSKY T., MONICK M., ENGELHARDT J., HUNNINGHAKE G.
JOURNAL OF IMMUNOLOGY, vol.169, no.11, pp.6539-6545, 2002 (SCI-Expanded)
- LXVIII. **Mitochondrial K-ATP channel openers activate the ERK kinase by an oxidant-dependent mechanism**
SAMAVATI L., MONICK M., Sanlioglu S., BUETTNER G., OBERLEY L., HUNNINGHAKE G.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, vol.283, no.1, 2002 (SCI-Expanded)
- LXIX. **PTEN as a diagnostic tool for the prognosis of prostate carcinomas**
DIRICE E., Koksal T., YASAR D., Ozes O. N., Baykara M., LULECI G., Sanlioglu S.
INTERNATIONAL JOURNAL OF CANCER, pp.372, 2002 (SCI-Expanded)

- LXXX. **Simultaneous inhibition of Rac1 and IKK pathways sensitizes lung cancer cells to TNF alpha-mediated apoptosis**
Sanlioglu S., LULECI G., THOMAS K.
CANCER GENE THERAPY, vol.8, no.11, pp.897-905, 2001 (SCI-Expanded)
- LXXI. **GPx-1 regulated intracellular hydrogen peroxide level specifically modulates IKK-alpha activity**
LI Q., Sanlioglu S., LI S., RITCHIE T., OBERLEY L., ENGELHARDT J.
MOLECULAR BIOLOGY OF THE CELL, vol.12, 2001 (SCI-Expanded)
- LXXII. **Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B**
Sanlioglu S., WILLIAMS C., SAMAVATI L., BUTLER N., WANG G., MCCRAY P., RITCHIE T., HUNNINGHAKE G., ZANDI E., ENGELHARDT J.
JOURNAL OF BIOLOGICAL CHEMISTRY, vol.276, no.32, pp.30188-30198, 2001 (SCI-Expanded)
- LXXIII. **Rate limiting steps of AAV transduction and implications for human gene therapy.**
Sanlioglu S., MONICK M. M., LULECI G., HUNNINGHAKE G. W., ENGELHARDT J. F.
Current gene therapy, vol.1, pp.137-47, 2001 (SCI-Expanded)
- LXXIV. **GPx-1 gene delivery modulates NF kappa B activation following diverse environmental injuries through a specific subunit of the IKK complex**
LI Q., Sanlioglu S., LI S., RITCHIE T., OBERLEY L., ENGELHARDT J.
ANTIOXIDANTS & REDOX SIGNALING, vol.3, no.3, pp.415-432, 2001 (SCI-Expanded)
- LXXV. **Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation**
Sanlioglu S., BENSON P., ENGELHARDT J.
VIROLOGY, vol.268, no.1, pp.68-78, 2000 (SCI-Expanded)
- LXXVI. **Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways**
Sanlioglu S., ENGELHARDT J.
GENE THERAPY, vol.6, no.8, pp.1427-1437, 1999 (SCI-Expanded)
- LXXVII. **Selective disruption of "late onset" sagittal banding patterns by ectopic expression of Engrailed-2 in cerebellar Purkinje cells**
BAADER S., VOGEL M., Sanlioglu S., ZHANG X., OBERDICK J.
JOURNAL OF NEUROSCIENCE, vol.19, no.13, pp.5370-5379, 1999 (SCI-Expanded)
- LXXVIII. **Two independent molecular pathways for recombinant adeno-associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction**
Sanlioglu S., DUAN D., ENGELHARDT J.
HUMAN GENE THERAPY, vol.10, no.4, pp.591-602, 1999 (SCI-Expanded)
- LXXIX. **Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression**
DUAN D., SHARMA P., DUDUS L., ZHANG Y., Sanlioglu S., YAN Z., YUE Y., YE Y., LESTER R., YANG J., et al.
JOURNAL OF VIROLOGY, vol.73, no.1, pp.161-169, 1999 (SCI-Expanded)
- LXXX. **Regulation of a Purkinje cell-specific promoter by homeodomain proteins: Repression by engrailed-2 vs. synergistic activation by HoxA5 and HoxB7**
Sanlioglu S., ZHANG X., BAADER S., OBERDICK J.
JOURNAL OF NEUROBIOLOGY, vol.36, no.4, pp.559-571, 1998 (SCI-Expanded)
- LXXXI. **Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions**
BAADER S., Sanlioglu S., BERREBI A., PARKER-THORNBURG J., OBERDICK J.
JOURNAL OF NEUROSCIENCE, vol.18, no.5, pp.1763-1773, 1998 (SCI-Expanded)
- LXXXII. **Functional cloning of candidate genes that regulate Purkinje cell-specific gene expression**
SanliogluCisman S., OBERDICK J.
CEREBELLUM: FROM STRUCTURE TO CONTROL, vol.114, pp.3-19, 1997 (SCI-Expanded)
- LXXXIII. **ACTIVATION OF A PURKINJE-CELL SPECIFIC GENE BY HOMEobox PROTEINS**

- SANLIOGLUCRISMAN S., OBERDICK J.
MOLECULAR BIOLOGY OF THE CELL, vol.6, pp.2000, 1995 (SCI-Expanded)
- LXXXIV. LOCAL-CONTROL OF GRANULE CELL GENERATION BY CEREBELLAR PURKINJE-CELLS
SMEYNE R., CHU T., LEWIN A., BIAN F., SANLIOGLU S., KUNSCH C., LIRA S., OBERDICK J.
MOLECULAR AND CELLULAR NEUROSCIENCE, vol.6, no.3, pp.230-251, 1995 (SCI-Expanded)
- LXXXV. Isolation of *Acinetobacter lwoffi* from Hens with Septicemia
KAYA O., ATES M., ERGANIS O., ÇORLU M., Sanlioglu S.
Journal of Veterinary Medicine, Series B, vol.36, no.1-10, pp.157-158, 1989 (SCI-Expanded)

Articles Published in Other Journals

- I. Kök Hücrelerde Programlanabilir Nükleazlarla Genom Mühendisliği Uygulamaları ve Yeni Bir İnsülin Gen Nakli Hastalık Modeli Oluşturma
EKŞİ Y. E., ŞANLIOĞLU S.
Türkiye Klinikleri İmmünoloji Alerji - Özel Konular, vol.1, no.1, pp.79-88, 2019 (Peer-Reviewed Journal)
- II. Expression profiles of TRAIL and its receptors in normal, hyperplastic, and malignant endometrial tissues: Hints on endometrial cancer biology
AYDIN ACAR Ç., BİŞGİN A., ŞANLIOĞLU A. D., PEŞTERELİ H. E., ERDOĞAN G., ÖZBUDAK Ö., ŞİMŞEK T., ŞANLIOĞLU S.
EASTERN JOURNAL OF MEDICINE, vol.24, no.3, pp.361-370, 2019 (Scopus)
- III. Vasoactive Intestinal Peptide-mediated Gene Therapy for Diabetes
ŞANLIOĞLU S.
JOURNAL OF THE PANCREAS, no.15, pp.534, 2014 (Peer-Reviewed Journal)

Books & Book Chapters

- I. High-Titer Production of HIV-Based Lentiviral Vectors in Roller Bottles for Gene and Cell Therapy
Olgun H. B., TAŞYÜREK M. H., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
in: Skin Stem Cell, Kursad Turksen, Editor, Humana Press, Inc. , New York, pp.323-345, 2019
- II. Methods in High-Grade Purification of Third-Generation HIV-Based Lentiviral Vectors by Anion Exchange Chromatography for Experimental Gene and Stem Cell Therapy ApplicationsMolecular Biology
Olgun H. B., TAŞYÜREK M. H., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
in: Skin Stem Cell, Kursad Turksen, Editor, Humana Press, Inc. , New York, pp.347-365, 2019
- III. Gen Tedavisi
ŞANLIOĞLU S.
in: Tibbi Genetik ve Klinik Uygulamaları, Dündar M., Editor, Ufuk Kitap Kırtasiye Yayıncılık Tic. Tur. Ltd. Şti., Türkiye, pp.409-434, 2016
- IV. Diyabet tedavisinde inkretin tabanlı gen tedavi stratejileri
ŞANLIOĞLU S.
in: Geçmişten Geleceğe Diabetes Mellitus, İmamoğlu Ş., Satman İ., Akalın S., Salman S., Yılmaz C., Editor, Türkiye Endokrinoloji Ve Metabolizma Der Yayınları, Ankara, pp.603-614, 2015

Refereed Congress / Symposium Publications in Proceedings

- I. Development of a Chemical Agent Induced Retinal Degeneration Animal Model for Exploring Anti-Inflammatory Gene Transfer Strategies in Genetic Blindness
EREENDOR F., ŞAHİN E. Ö., BİLGİN A. B., ŞANLIOĞLU A. D., BOGA İ., BİŞGİN A., Öztürk B. E., CEYLANER S., ŞANLIOĞLU S.

18. Tibbi Biyoloji ve Genetik Kongresi, Ankara, Turkey, 26 - 29 October 2023
- II. **The Protective Role of Vasoactive Intestinal Peptide on Neuronal Cells Against Toxic Effects of MPTP, Hydrogen Peroxide, and Microglial Secretome**
Durkaya Z. H., GÖKSU EROL A. Y., AKINCI E., KOÇANCI F. G., DEMİR DORA D., AKÇAKALE F., ELLİDAĞ H. Y., ŞANLIOĞLU S., UYSAL H.
XVII. Congress of Medical Biology and Genetics, Turkey, 28 - 30 October 2021
- III. **Treatment of microglia with Vasoactive Intestinal Peptide provides protection against microglia-associated neurotoxicity**
GÖKSU EROL A. Y., KOÇANCI F. G., AKINCI E., DEMİR DORA D., ERENDOR F., ŞANLIOĞLU S., UYSAL H.
XVII. Congress of Medical Biology and Genetics, Turkey, 28 - 30 October 2021
- IV. **Treatment of microglia with Vasoactive Intestinal Peptide provides protection against microglia-associated neurotoxicity**
GÖKSU EROL A. Y., KOÇANCI F. G., AKINCI E., DEMİR DORA D., ERENDOR F., ŞANLIOĞLU S.
XVII. Congress of Medical Biology and Genetics, Turkey, 28 - 30 October 2021
- V. **COVID-19 hastalığına karşı SARS-CoV-2 spike geni taşıyan lentiviral tabanlı aşısı plazmidinin oluşturulması**
ERENDOR F., ŞAHİN E. Ö., AKKAYA B., BİŞGİN A., DEMİR DORA D., KÖKSOY S., ORAL H. B., ŞANLIOĞLU S.
XVII. Tibbi Biyoloji ve Genetik Kongresi, 28 - 31 October 2021, vol.52, pp.100
- VI. **Construction of a Lentiviral Vector-carrying SARS-CoV-2 Spike Gene for COVID-19**
ERENDOR F., ŞAHİN E. Ö., AKKAYA B., BİŞGİN A., DEMİR DORA D., KÖKSOY S., ORAL H. B., ŞANLIOĞLU S.
28th Annual Congress of the ESGCT. Human Gene Therapy, 19 - 22 October 2021, vol.32
- VII. **Novel gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis.**
Abstract. P206. Athens, Greece, 2006.
Bisgin A., ŞANLIOĞLU A. D., Ulker M., YAZISIZ V., TÜZÜNER S., TERZİOĞLU M. E., ŞANLIOĞLU S.
XIV Annual Congress of the European Society of Gene Therapy,, Greece, vol.1, pp.206
- VIII. **Testing the efficacy of a novel adenovirus mediated TRAIL gene therapy approach for the treatment of patients with Type 1 Diabetes.**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KÖKSOY S.
Advances in Molecular Medicine, İstanbul, Turkey, pp.160
- IX. **Testing the efficacy of a novel adenovirus mediated TRAIL gene therapy approach for the treatment of patients with Type 1 Diabetes.**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KÖKSOY S.
Advances in Molecular Medicine, İstanbul, Turkey, pp.160
- X. **Efficient adenovirus mediated TRAIL gene delivery into pancreatic islets as a model for the treatment of patients with type 1 diabetes**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K.
13th Annual Congress of European Society of Gene Therapy, Czech Republic, pp.74
- XI. **TRAIL ligand and receptor expressions are differentially upregulated in prostate carcinoma patients: a significant issue for gene therapy of advanced prostate cancer**
ŞANLIOĞLU S., CIFTIOGLU A., ŞANLIOĞLU A. D., Lüleci G., KÖKSAL İ. T., BAYKARA M., BAŞSORUN C. İ.
13th Annual Congress of European Society of Gene Therapy, Czech Republic, pp.22
- XII. **Adenovirus mediated TRAIL gene delivery as a gene therapy model for patients with advanced prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
Advances in Molecular Medicine, İstanbul, Turkey, pp.14
- XIII. **Adenovirus mediated IKK β KA expression sensitizes advanced prostate carcinoma cells to TRAIL-Mediated apoptosis in spite of decoy receptor gene expression**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
Advances in Molecular Medicine, İstanbul, Turkey, pp.165
- XIV. **Decoy receptor gene expression as a chief mechanism to govern TRAIL resistance in advanced prostate carcinoma**

- ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
13th Annual Congress of European Society of Gene Therapy, Czech Republic, pp.23
- XV. **Adenovirus mediated NF-κB inhibiting strategies for the treatment of patients with type 1 diabetes**
ŞANLIOĞLU S., YOLDAŞ ÇELİKTEKİN S. B.
13th Annual Congress of European Society of Gene Therapy, Czech Republic, pp.88
- XVI. **Novel gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis.**
Abstract. P206. Athens, Greece, 2006.
Bisgin A., ŞANLIOĞLU A. D., Ulker M., YAZISIZ V., TÜZÜNER S., TERZİOĞLU M. E., ŞANLIOĞLU S.
XIV Annual Congress of the European Society of Gene Therapy,, Greece, vol.1, pp.206
- XVII. **. “Expression Profile of TRAIL and its Receptors in Breast Cancer patients with invasive ductal carcinoma” Vol. 5 (4), EJC Suplement Elsevier, 2007.**
SANLIOGLU A. D., KORCUM A. F., PEŞTERELİ H. E., ERDOĞAN G., KARAVELİ F. S., ŞANLIOĞLU S., SAVAŞ B., GRIFFTH T.
14th European Cancer Conference, Spain, pp.2136
- XVIII. **New gene therapy modalities targeting oxidative stress and microglial activation are needed for effective treatment of retinitis pigmentosa**
ŞAHİN E. Ö., ERENDOR F., BİŞGİN A., CEYLANER S., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc Meeting, Barcelona, Spain, 22 - 25 October 2019
- XIX. **LentiVIP Gen Nakli Tip 1 Diyabetik Deneklerde Sistemik Enflamasyonu Baskılayarak Kan Şekerini Düşürdü**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
16. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2019, pp.1
- XX. **LentiVIP Gen Nakli Tip 1 Diyabetik Deneklerde Sistemik Enflamasyonu Baskılayarak Kan Şekerini Düşürdü**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
16. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2019, pp.1
- XXI. **Retinitis Pigmentoza Gen Tedavi Çalışmalarında Kullanılmak Üzere Lentiviral Vektörlerin Geliştirilmesi ve Testi**
Şahin E. Ö., Erendor F., Bışgin A., Ceylaner S., Şanlıoğlu S.
16. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2019, pp.1
- XXII. **LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 21 - 25 October 2019
- XXIII. **LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc Meeting, Barcelona, Spain, 22 - 25 October 2019
- XXIV. **1- Lentivirus mediated insulin promoter directed insulin gene expression is effective in suppressing postprandial glucose excursions in Type 1 diabetes**
EKŞİ Y. E., ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 22 - 25 October 2019, pp.1
- XXV. **1- Lentivirus mediated insulin promoter directed insulin gene expression is effective in suppressing postprandial glucose excursions in Type 1 diabetes**
EKŞİ Y. E., ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 22 - 25 October 2019, pp.1
- XXVI. **New gene therapy modalities targeting oxidative stress and microglial activation are needed for effective treatment of retinitis pigmentosa**
Şahin E. Ö., Erendor F., Bilgin A. B., Ceylaner S., Şanlıoğlu S.
ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 22 - 25 October 2019, pp.1
- XXVII. **3- New gene therapy modalities targeting oxidative stress and microglial activation are needed for**

- effective treatment of retinitis pigmentosa**
ŞAHİN E. Ö., ERENDOR F., BİŞGİN A., CEYLANER S., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 22 - 25 October 2019, pp.1
- XXVIII. LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 22 - 25 October 2019, pp.1
- XXIX. LentiVIP delivery suppresses systemic inflammation which results in beneficial outcome in Type 1 Diabetes**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT 27th Annual Congress in collaboration with SETGyc, Barcelona, Spain, 22 - 25 October 2019, pp.1
- XXX. Development of MODY10 diabetic experimental animal model using CRISPR/Cas9 technology for insulin gene transfer studies**
Eksi Y. E., Altunbas H. A., ŞANLIOĞLU S.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017, vol.28
- XXXI. Development of a gene therapy vector to provide insulin expression from induced pluripotent stem cells**
Gumuslu E., BALCI M. K., ŞANLIOĞLU S.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017, vol.28
- XXXII. A practical method for production and purification of 3rd generation HIV based lentiviral vectors for In vivo applications**
Olgun H. B., BALCI M. K., ŞANLIOĞLU S.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017, vol.28
- XXXIII. Generation of a lentiviral vector encoding vasoactive intestinal peptide for type 1 diabetes**
Erendor F., Sahin E. O., BALCI M. K., ŞANLIOĞLU S.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017, vol.28
- XXXIV. Multiple low-dose streptozotocin injections induced diabetes in Wistar rats characterised by insulitis and hyperglycaemia useful for gene transfer studies**
Sahin E. O., Erendor F., BALCI M. K., ŞANLIOĞLU S.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017, vol.28
- XXXV. Generation of a beta cell specific insulin gene therapy vector for diabetes**
Sahin E. O., Erendor F., BALCI M. K., ŞANLIOĞLU S.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017, vol.28
- XXXVI. Glucagon like peptide-1 as an antidiabetic gene therapy agent inducing transdifferantiation of pancreatic endocrine cells**
Tasyurek H. M., Altunbas H. A., ŞANLIOĞLU S.
European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Germany, 01 January 2017, vol.28
- XXXVII. Development of a gene therapy vector to provide insülin expression from induced pluripotent stem GÜMÜŞLÜ E., BALCI M. K., ŞANLIOĞLU S.**
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 November 2017, pp.357
- XXXVIII. Development of a gene therapy vector to provide insülin expression from induced pluripotent stem GÜMÜŞLÜ E., BALCI M. K., ŞANLIOĞLU S.**
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 November 2017, pp.357
- XXXIX. Antidiyabetik gen nakil çalışmalarında kullanılmak üzere çoklu düşük doz Streptozotosin uygulamasıyla otoimmunitenin induklendiği Wistar sıçan modelinin geliştirilmesi**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.1
- XL. Tip 1 diyabet için vazoaktif intestinal peptidi kodlayan lentiviral vektörün geliştirilmesi.**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017
- XLI. Antidiyabetik gen terapi ajanı olarak Glukagon Benzeri Peptid-1 ve hücresel transdiferansiyasyon.**

- TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 October - 29 November 2017
- XLII. **İndüklenmiş pluripotent kök hücrelerden insülin sentezini sağlayan gen tedavi vektörünün geliştirilmesi.**
GÜMÜŞLÜ E., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017
- XLIII. **Antidiyabetik gen nakil çalışmalarında kullanılmak üzere çoklu duşuk doz Streptozotosin uygulamasıyla otoimmunitenin induklendiği Wistar sıçan modelinin geliştirilmesi**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.1
- XLIV. **Diyabet hastalığına karşı kullanılmak üzere beta hücre spesifik gen tedavi vektörünün oluşturulması**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.1
- XLV. **Diyabet hastalığına karşı kullanılmak üzere beta hücre spesifik gen tedavi vektörünün oluşturulması**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 October - 29 November 2017, pp.8
- XLVI. **3. jenerasyon HIV tabanlı lentiviral vektörlerin in vivo uygulamalar için uretimi ve prifikasyon yöntemlerinin optimizasyonu**
Olgun H. B., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017
- XLVII. **Antidiyabetik gen terapi ajansı olarak Glukagon Benzeri Peptid-1 ve hücresel transdiferansiyasyon.**
TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 October - 29 November 2017
- XLVIII. **İndüklenmiş pluripotent kök hücrelerden insülin sentezini sağlayan gen tedavi vektörünün geliştirilmesi.**
GÜMÜŞLÜ E., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017
- XLIX. **İnsulin gen replasman tedavisinde kullanılmak üzere CRISPR- Cas9 yöntemiyle MODY10 diyabetik deney hayvan modeli oluşturma**
EKŞİ Y. E., ALTUNBAŞ H. A., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.12
- L. **3. jenerasyon HIV tabanlı lentiviral vektörlerin in vivo uygulamalar için uretimi ve prifikasyon yöntemlerinin optimizasyonu**
Olgun H. B., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.10
- LI. **Tip 1 diyabet için vazoaktif intestinal peptidi kodlayan lentiviral vektörün geliştirilmesi**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.1
- LII. **Antidiyabetik gen nakil çalışmalarında kullanılmak üzere çoklu duşuk doz Streptozotosin uygulamasıyla otoimmunitenin induklendiği Wistar sıçan modelinin geliştirilmesi**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 October - 29 November 2017
- LIII. **Antidiyabetik gen nakil çalışmalarında kullanılmak üzere çoklu duşuk doz Streptozotosin uygulamasıyla otoimmunitenin induklendiği Wistar sıçan modelinin geliştirilmesi**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 October - 29 November 2017
- LIV. **Tip 1 diyabet için vazoaktif intestinal peptidi kodlayan lentiviral vektörünün geliştirilmesi.**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017
- LV. **Diyabet hastalığına karşı kullanılmak üzere beta hücre spesifik gen tedavi vektörünün oluşturulması**

- ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 October - 29 November 2017, pp.8
- LVI. **3. jenerasyon HIV tabanlı lentiviral vektörlerin in vivo uygulamalar için üretimi ve pürifikasyon yöntemlerinin optimizasyonu**
Olgun H. B., BALCI M. K., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.10
- LVII. **İnsulin gen replasman tedavisinde kullanılmak üzere CRISPR- Cas9 yöntemiyle MODY10 diyabetik deney hayvan modeli oluşturma**
EKŞİ Y. E., ALTUNBAŞ H. A., ŞANLIOĞLU S.
15. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 26 - 29 October 2017, pp.12
- LVIII. **Generation of a beta cell-specific insulin gene therapy vector for diabetes**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
European Society of Gene and Cell Therapy (ESGCT) XXV Anniversary Congress, Berlin, Germany, 17 - 21 October 2017
- LIX. **Multiple low-dose streptozotocin injections induced diabetes in Wistar rats characterised by insulitis and hyperglycaemia useful for gene transfer studies**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
ESGCT Avrupa Gen Tedavi Kongresi, Berlin, Germany, 17 - 21 October 2017
- LX. **Generation of a beta cell specific insulin gene therapy vector for diabetes**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 October - 20 November 2017, pp.341
- LXI. **Multiple low-dose streptozotocin injections induced diabetes in Wistar rats characterised by insulitis and hyperglycaemia useful for gene transfer studies**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 21 October 2017, pp.113
- LXII. **Generation of a lentiviral vector encoding vasoactive intestinal peptide for type 1 diabetes**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
European Society of Gene and Cell Therapy (ESGCT) XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.1
- LXIII. **Glucagon like peptide-1 as an antidiabetic gene therapy agent inducing transdifferantiation of pancreatic endocrine cells**
TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.277
- LXIV. **Development of MODY10 diabetic experimental animal model using CRISPR/Cas9 technology for insulin gene transfer studies**
EKŞİ Y. E., ALTUNBAŞ H. A., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.112
- LXV. **Glucagon like peptide-1 as an antidiabetic gene therapy agent inducing transdifferantiation of pancreatic endocrine cells**
TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.277
- LXVI. **Development of MODY10 diabetic experimental animal model using CRISPR/Cas9 technology for insulin gene transfer studies**
EKŞİ Y. E., ALTUNBAŞ H. A., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.112
- LXVII. **Generation of a lentiviral vector encoding vasoactive intestinal peptide for type 1 diabetes**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.152
- LXVIII. **Generation of a beta cell specific insulin gene therapy vector for diabetes**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 October - 20 November 2017, pp.341

- LXIX. **Generation of a beta cell specific insulin gene therapy vector for diabetes", ESGCT XXV Anniversary Congress**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
European Society of Gene and Cell Therapy (ESGCT) XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.1
- LXX. **Generation of a lentiviral vector encoding vasoactive intestinal peptide for type 1 diabetes**
ERENDOR F., ŞAHİN E. Ö., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.152
- LXXI. **A practical method for production and purification of 3rd generation HIV based lentiviral vectors for In vivo applications**
Olgun H. B., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.176
- LXXII. **Multiple low-dose streptozotocin injections induced diabetes in Wistar rats characterised by insulitis and hyperglycaemia useful for gene transfer studies**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 21 October 2017, pp.113
- LXXIII. **Multiple low-dose streptozotocin injections induced diabetes in Wistar rats characterised by insulitis and hyperglycaemia useful for gene transfer studies**
ŞAHİN E. Ö., ERENDOR F., BALCI M. K., ŞANLIOĞLU S.
European Society of Gene and Cell Therapy (ESGCT) ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 21 October 2017, pp.1
- LXXIV. **A practical method for production and purification of 3rd generation HIV based lentiviral vectors for In vivo applications**
Olgun H. B., BALCI M. K., ŞANLIOĞLU S.
ESGCT XXV Anniversary Congress, Berlin, Germany, 17 - 20 October 2017, pp.176
- LXXV. **Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.9
- LXXVI. **Kök hücre kaynaklı pankreatik beta hücrelerinde uzun süreli insülin gen ekspresyonu yapabilen lentiviral gen tedavi vektörlerinin geliştirilmesi**
GÜMÜŞLÜ E., TAŞYÜREK M. H., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.12
- LXXVII. **Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.249
- LXXVIII. **Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması**
OLGUN H. B., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.6
- LXXIX. **Diyabet Hastalığına karşı geliştirilen gen tedavi stratejilerinde kullanılmak üzere tip 1 diyabet hayvan modelinin oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., Erendor F., ALTUNBAŞ H. A., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.251
- LXXX. **Diyabet hastalığına karşı geliştirilen gen tedavi stratejilerinde kullanılmak üzere Tip 1 Diyabet hayvan modelinin oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., ERENDOR F., ALTUNBAŞ H. A., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.1
- LXXXI. **Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması**

- TAŞYÜREK M. H., EKİSİ Y. E., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.249
- LXXXII. **İnkretin gen nakli diyabetik deneklerde insülin direncini kırıp glukoz toleransını geliştirerek beta hücre rejenerasyonu sağlar**
TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.250
- LXXXIII. **Diyabette insülin gen tedavi stratejileri**
ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.117-118
- LXXXIV. **Kök hücre kaynaklı pankreatik beta hücrelerinde uzun süreli insülin gen ekspresyonu yapabilen lentiviral gen tedavi vektörlerinin geliştirilmesi**
Gümüşlü E., TAŞYÜREK M. H., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.252
- LXXXV. **Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKİSİ Y. E., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.9
- LXXXVI. **Diyabet tedavisinde in vivo gen nakil uygulamalarına uygun ölçekte ve kalitede lentiviral vektör üretimi**
OLGUN H. B., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.6
- LXXXVII. **Kök hücre kaynaklı pankreatik beta hücrelerinde uzun süreli insülin gen ekspresyonu yapabilen lentiviral gen tedavi vektörlerinin geliştirilmesi**
Gümüşlü E., TAŞYÜREK M. H., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.252
- LXXXVIII. **İnkretin gen nakli diyabetik deneklerde insülin direncini kırıp glukoz toleransını geliştirerek beta hücre rejenerasyonu sağlar**
TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.10
- LXXXIX. **Diyabet hastalığına karşı geliştirilen gen tedavi stratejilerinde kullanılmak üzere Tip 1 Diyabet hayvan modelinin oluşturulması**
TAŞYÜREK M. H., EKİSİ Y. E., ERENDOR F., ALTUNBAŞ H. A., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.11
- XC. **Diyabet Hastalığına karşı geliştirilen gen tedavi stratejilerinde kullanılmak üzere tip 1 diyabet hayvan modelinin oluşturulması**
TAŞYÜREK M. H., EKİSİ Y. E., Erendor F., ALTUNBAŞ H. A., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.251
- XCI. **Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKİSİ Y. E., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.9
- XCII. **Diyabet hastalığına karşı geliştirilen gen tedavi stratejilerinde kullanılmak üzere Tip 1 Diyabet hayvan modelinin oluşturulması**
TAŞYÜREK M. H., EKİSİ Y. E., ERENDOR F., ALTUNBAŞ H. A., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Turkey, 19 - 23 April 2017, pp.11
- XCIII. **Pankreatik beta hücrelerine özgün insülin promotorlu proinsülin gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKİSİ Y. E., BALCI M. K., ŞANLIOĞLU S.
53. Ulusal Diyabet Kongresi, Girne, Cyprus (Kktc), 19 - 23 April 2017, pp.249
- XCIV. **Glucagon like peptide-1 gene delivery increases beta cell replication and neogenesis in Type 2 Diabetic Obese Sprague Dawley Rats**

- Tasyurek H. M., Altunbas H. A., ŞANLIOĞLU S.
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, Italy, 18 - 21 October 2016, vol.27
- XCV. **Generation of a lentiviral vector encoding human insulin for diabetes treatment**
Eksi Y. E., BALCI M. K., ŞANLIOĞLU S.
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, Italy, 18 - 21 October 2016, vol.27
- XCVI. **Novel approaches for insulin mediated gene delivery in diabetes treatment**
Eksi Y. E., BALCI M. K., ŞANLIOĞLU S.
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, Italy, 18 - 21 October 2016, vol.27
- XCVII. **Glucagon like peptide-1 gene delivery increases beta cell replication and neogenesis in Type 2 Diabetic Obese Sprague Dawley Rats**
TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy., Floransa, Italy, 18 - 21 October 2016, vol.27, no.11
- XCVIII. **Glucagon like peptide-1 gene delivery increases beta cell replication and neogenesis in Type 2 Diabetic Obese Sprague Dawley Rats**
TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy., Floransa, Italy, 18 - 21 October 2016, vol.27, no.11
- XCIX. **Pankreatik beta hücre hedefli HIV tabanlı insülin gen tedavi vektörünün oluşturulması**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.206
- C. **Diyabet Tedavisinde inkretin tabanlı gen tedavi stratejileri.**
ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.67-68
- CI. **EF-1 promotoru kontrolünde insulin gen ekspresyonu yapan HIV tabanlı lentiviral gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.200
- CII. **Pankreatik beta hücre hedefli HIV tabanlı insülin gen tedavi vektörünün oluşturulması**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.206
- CIII. **EF-1 promotoru kontrolünde insulin gen ekspresyonu yapan HIV tabanlı lentiviral gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.200
- CIV. **EF-1 promotoru kontrolünde insulin gen ekspresyonu yapan HIV tabanlı lentiviral gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.200
- CV. **Pankreatik beta hücre hedefli HIV tabanlı insülin gen tedavi vektörünün oluşturulması**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.206
- CVI. **Pankreatik beta hücre hedefli HIV tabanlı insülin gen tedavi vektörünün oluşturulması**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.206
- CVII. **EF-1 promotoru kontrolünde insulin gen ekspresyonu yapan HIV tabanlı lentiviral gen tedavi vektörünün oluşturulması**
TAŞYÜREK M. H., EKŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.

- Uluslararası Katılımlı 12. Ulusal Tıbbi Genetik Kongresi, İzmir, Turkey, 5 - 09 October 2016, vol.2, pp.200
- CVIII. **Current progress in incretin mediated gene therapy approach**
ŞANLIOĞLU S.
Uluslararası Katkılı Gevher Nesibe Tıp Günleri Tıbbi Genetik ve Klinik Uygulamaları Kongresi, Kayseri, Turkey, 11 - 13 February 2016, vol.38, no.1
- CIX. **GLP1 gen replasman tedavisinin Tip 2 Diyabet Sprague Dawley Sıçanlarda rezidüel adacık replikasyon ve rejenerasyonu üzerindeki etkisinin incelenmesi**
OLGUN H. B., TAŞYÜREK M. H., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
XIV. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2015, pp.146
- CX. **3. Jenerasyon Lentivirus aracılı Vazoaktif İntestinal Peptid gen naklinin obezite bağımlı Tip 2 Diyabet deney hayvan modelinde terapötik etkinliği**
ŞANLIOĞLU S.
14. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2015
- CXI. **Diyabet Tedavisinde HIV tabanlı lentivirus aracılı Glukagon benzeri peptid-1 gen aktarımının terapötik etkileri**
TAŞYÜREK M. H., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
XIV. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2015, pp.145
- CXII. **GLP1 gen replasman tedavisinin Tip 2 Diyabet Sprague Dawley Sıçanlarda rezidüel adacık replikasyon ve rejenerasyonu üzerindeki etkisinin incelenmesi**
OLGUN H. B., TAŞYÜREK M. H., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
XIV. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2015, pp.146
- CXIII. **Diyabet Tedavisinde HIV tabanlı lentivirus aracılı Glukagon benzeri peptid-1 gen aktarımının terapötik etkileri**
TAŞYÜREK M. H., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
XIV. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 27 - 30 October 2015, pp.145
- CXIV. **Vasoactive intestinal peptide gene delivery for diabetes treatment**
ŞANLIOĞLU S., taşyürek h., BALCI M. K.
Molecular Biologu and Genetics Congress, İstanbul, Turkey, 2 - 04 October 2015, pp.10
- CXV. **Vasoactive intestinal peptide gene delivery for diabetes treatment**
ŞANLIOĞLU S., taşyürek h., BALCI M. K.
Molecular Biologu and Genetics Congress, İstanbul, Turkey, 2 - 04 October 2015, pp.10
- CXVI. **Obese and diabetic sprague dawley rats exhibited reduced GLP-1 expression in pancreatic islets of Langerhans**
Olgun H. B., Tasyurek H. M., Altunbas H. A., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finland, 17 - 20 September 2015, vol.26
- CXVII. **Therapeutic outcomes of an HIV-based lentivirus mediated Glucagon-like peptide-1 gene delivery for diabetes treatment**
Tasyurek H. M., Altunbas H. A., CANATAN H., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finland, 17 - 20 September 2015, vol.26
- CXVIII. **In vivo distribution of HIV based 3rd generation of lentiviral vectors used in gene therapy in DOI animal model of type 2 diabetes**
Eksi Y. E., Tasyurek H. M., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finland, 17 - 20 September 2015, vol.26
- CXIX. **Obese and diabetic sprague dawley rats exhibited reduced GLP-1 expression in pancreatic islets of Langerhans**
Olgun H. B., TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress, 2015, Helsinki, Finland, 17 - 20 September 2015
- CXX. **In vivo distribution of HIV based 3rd generation of lentiviral vectors used in gene therapy in DOI**

- animal model of type 2 diabetes**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress,2015, Helsinki, Finland, 17 - 20 September 2015
- CXXI. **Obese and diabetic sprague dawley rats exhibited reduced GLP-1 expression in pancreatic islets of Langerhans**
Olgun H. B., TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress,2015, Helsinki, Finland, 17 - 20 September 2015
- CXXII. **Therapeutic outcomes of an HIV-based lentivirus mediated Glucagon-like peptide-1 gene delivery for diabetes treatment**
TAŞYÜREK M. H., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress, Helsinki, Finland, 17 - 20 September 2015
- CXXIII. **In vivo distribution of HIV based 3rd generation of lentiviral vectors used in gene therapy in DOI animal model of type 2 diabetes**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress,2015, Helsinki, Finland, 17 - 20 September 2015
- CXXIV. **In vivo distribution of HIV based 3rd generation of lentiviral vectors used in gene therapy in DOI animal model of type 2 diabetes**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress,2015, Helsinki, Finland, 17 - 20 September 2015
- CXXV. **In vivo distribution of HIV based 3rd generation of lentiviral vectors used in gene therapy in DOI animal model of type 2 diabetes**
EKŞİ Y. E., TAŞYÜREK M. H., BALCI M. K., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress,2015, Helsinki, Finland, 17 - 20 September 2015
- CXXVI. **Therapeutic outcomes of an HIV-based lentivirus mediated Glucagon-like peptide-1 gene delivery for diabetes treatment**
TAŞYÜREK M. H., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
ESGCT and FSGCT Collaborative Congress,2015, Helsinki, Finland, 17 - 20 September 2015
- CXXVII. **Diyabet tedavisi için insan Glukagon Benzeri Peptid-1 kodlayan lentiviral vektörlerin üretimi**
ŞANLIOĞLU S., ALTUNBAŞ H. A., TAŞYÜREK M. H.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015
- CXXVIII. **Gen tedavisinde kullanılan lentivlral vektörlerin in vivo dağılımlarının Tip 2 Diyabet hayvan modelinde belirlenmesi**
TAŞYÜREK M. H., EKŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.146-147
- CXXIX. **Diyabet tedavisi için insan Glukagon Benzeri Peptid-1 kodlayan lentiviral vektörlerin üretimi**
ŞANLIOĞLU S., ALTUNBAŞ H. A., TAŞYÜREK M. H.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015
- CXXX. **HİV tabanlı Lentivirus aracılı Vazoaktif İntestinal Peptid gen nakli obez farelerde insulin direncini kırıp glukoz toleransı geliştirerek STZ induklü diyabet gelişimini durdurdu**
ŞANLIOĞLU S.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015
- CXXXI. **Diyet bağımlı obez Sprague Dawley sincanlarda STZ ile diyabet indüksiyonu pankreatik adacıklarda inkretin hormonu (GLP-1) sentezini azaltır**
OLGUN H. B., TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.146
- CXXXII. **Diyet bağımlı obez Sprague Dawley sincanlarda STZ ile diyabet indüksiyonu pankreatik adacıklarda inkretin hormonu (GLP-1) sentezini azaltır**
OLGUN H. B., TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.146
- CXXXIII. **Gen tedavisinde kullanılan lentivlral vektörlerin in vivo dağılımlarının Tip 2 Diyabet hayvan modelinde belirlenmesi**

- TAŞYÜREK M. H., EKİŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.146-147
- CXXXIV. **Gen tedavisinde kullanılan lentiviral vektörlerin in vivo dağılımlarının Tip 2 Diyabet hayvan modelinde belirlenmesi**
TAŞYÜREK M. H., EKİŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.146-147
- CXXXV. **Gen tedavisinde kullanılan lentiviral vektörlerin in vivo dağılımlarının Tip 2 Diyabet hayvan modelinde belirlenmesi**
TAŞYÜREK M. H., EKİŞİ Y. E., BALCI M. K., ŞANLIOĞLU S.
51. Ulusal Diyabet Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.146-147
- CXXXVI. **Construction of A lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKİŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
EMBO Workshop, Evry, France, 30 March - 04 April 2015, pp.185
- CXXXVII. **Construction of A lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKİŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
EMBO Workshop, Evry, France, 30 March - 04 April 2015, pp.185
- CXXXVIII. **Construction of A lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKİŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
EMBO Workshop, Evry, France, 30 March - 04 April 2015, pp.185
- CXXXIX. **Construction of A lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKİŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
EMBO Workshop, Evry, France, 30 March - 04 April 2015, pp.185
- CXL. **Comparative efficacy of diet induced obesity in C57BL/6J versus Balb/C mice for gene therapy applications**
Eksi Y. E., Tasyurek H. M., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, vol.25
- CXLI. **Up-regulation of Glucagon Like Peptide-1 Expression in pancreases of C57BL6J Mice with Diabetes**
Tasyurek H. M., Eksi Y. E., Altunbas H. A., BALCI M. K., ŞANLIOĞLU S.
ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, vol.25
- CXLII. **Induction of Diet Induced Obesity in Sprague Dawley Rats as a Model for Type 2 Diabetes**
Eksi Y. E., Tasyurek H. M., Altunbas H. A., ŞANLIOĞLU S.
ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, vol.25
- CXLIII. **Generation of A Lentiviral Vector Encoding Human Glucagon Like Peptide-1 (GLP-1) for Diabetes Treatment**
Tasyurek H. M., Eksi Y. E., Altunbas H. A., BALCI M. K., ŞANLIOĞLU S.
ESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, vol.25
- CXLIV. **Induction of Diet Induced Obesity in Sprague Dawley Rats as a Model of Type 2 Diabetes**
EKİŞİ Y. E., TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CXLV. **Comperative efficacy of Diet Induced Obesity in c57bl/6j versus Balb/C mice for gene Threapy applications**
EKİŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CXLVI. **Comperative efficacy of Diet Induced Obesity in c57bl/6j versus Balb/C mice for gene Threapy applications**
EKİŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014

- CXLVII. **Generation of A Lentiviral Vector Encoding Human Glucagon Like Peptide-1 (GLP-1) for Diabetes Treatment**
TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
ESGCT AND NVGCT COLLABORATIVE CONGRESS, 2014, The Hague, Amsterdam, Netherlands, 23 - 26 October 2014, vol.25, no.11, pp.87-88
- CXLVIII. **Construction of A Lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Human Gene TherapyESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, pp.123
- CXIX. **Up Regulation of Glucagon Like Peptide-1 Expression in Pancreases of C57BL6j Mice with Diabetes**
TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CL. **Construction of A Lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Human Gene TherapyESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, pp.123
- CLI. **Construction of A Lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Human Gene TherapyESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, pp.123
- CLII. **Induction of Diet Induced Obesity in Sprague Dawley Rats as a Model of Type 2 Diabetes**
EKŞİ Y. E., TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CLIII. **Induction of Diet Induced Obesity in Sprague Dawley Rats as a Model of Type 2 Diabetes**
EKŞİ Y. E., TAŞYÜREK M. H., ALTUNBAŞ H. A., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CLIV. **Comperative efficacy of Diet Induced Obesity in c57bl/6j versus Balb/C mice for gene Threapy applications**
EKŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CLV. **Construction of A Lentiviral Vector Encoding Human Vasoactive Intestinal Peptide for Diabetes Treatment**
EKŞİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Human Gene TherapyESGCT and NVGCT Collaborative Congress, The Hague, Netherlands, 23 - 26 October 2014, pp.123
- CLVI. **Generation of A Lentiviral Vector Encoding Human Glucagon Like Peptide-1 (GLP-1) for Diabetes Treatment**
TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
ESGCT AND NVGCT COLLABORATIVE CONGRESS, 2014, The Hague, Amsterdam, Netherlands, 23 - 26 October 2014, vol.25, no.11, pp.87-88
- CLVII. **Up Regulation of Glukagon Like Peptide-1 Expression in Pancreases of C57BL6j Mice with Diabetes**
TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CLVIII. **Therapeutic efficacy of an HIV-Based Lentivirus Mediated Vasoactive İntestinal Peptide Gene Delivery for Diabetes**
TAŞYÜREK M. H., EKŞİ Y. E., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014
- CLIX. **Generation of A Lentiviral Vector Encoding Human Glucagon Like Peptide-1 (GLP-1) for Diabetes**

Treatment

TAŞYÜREK M. H., EKİSİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.

ESGCT AND NVGCT COLLABORATIVE CONGRESS, 2014, The Hague, Amsterdam, Netherlands, 23 - 26 October 2014, vol.25, no.11, pp.87-88

- CLX. **Comperative efficacy of Diet Induced Obesity in c57bl/6j versus Balb/C mice for gene Threapy applications**

EKİSİ Y. E., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.

The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014

- CLXI. **Up Regulation of Glukagon Like Peptide-1 Expression in Pancreases of C57BL6j Mice with Diabetes**

TAŞYÜREK M. H., EKİSİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.

The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014

- CLXII. **Up Regulation of Glukagon Like Peptide-1 Expression in Pancreases of C57BL6j Mice with Diabetes**

TAŞYÜREK M. H., EKİSİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.

The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014

- CLXIII. **Generation of A Lentiviral Vector Encoding Human Glucagon Like Peptide-1 (GLP-1) for Diabetes Treatment**

TAŞYÜREK M. H., EKİSİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.

ESGCT AND NVGCT COLLABORATIVE CONGRESS, 2014, The Hague, Amsterdam, Netherlands, 23 - 26 October 2014, vol.25, no.11, pp.87-88

- CLXIV. **Therapeutic efficacy of an HIV-Based Lentivirus Mediated Vasoactive İntestinal Peptide Gene Delivery for Diabetes**

TAŞYÜREK M. H., EKİSİ Y. E., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.

The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014

- CLXV. **Therapeutic efficacy of an HIV-Based Lentivirus Mediated Vasoactive İntestinal Peptide Gene Delivery for Diabetes**

TAŞYÜREK M. H., EKİSİ Y. E., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.

The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014

- CLXVI. **Therapeutic efficacy of an HIV-Based Lentivirus Mediated Vasoactive İntestinal Peptide Gene Delivery for Diabetes**

TAŞYÜREK M. H., EKİSİ Y. E., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.

The XXII. Annual ESGCT Congress in collaboration with the NCGCT, Hague, Netherlands, 23 - 26 October 2014

- CLXVII. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**

ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKİSİ Y. E.

American Diabetes Association, San Francisco, United States Of America, 14 - 17 June 2014, pp.659

- CLXVIII. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**

ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKİSİ Y. E.

American Diabetes Association, San Francisco, United States Of America, 14 - 17 June 2014, pp.659

- CLXIX. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**

ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKİSİ Y. E.

American Diabetes Association, San Francisco, United States Of America, 14 - 17 June 2014, pp.659

- CLXX. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**

ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKİSİ Y. E.

American Diabetes Association, San Francisco, United States Of America, 14 - 17 June 2014, pp.659

- CLXXI. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**

EKİSİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.

American Diabetes Association, San Francisco, United States Of America, 13 - 17 June 2014, vol.63

- CLXXII. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**

EKİSİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.

American Diabetes Association, San Francisco, United States Of America, 13 - 17 June 2014, vol.63

- CLXXIII. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**

EKİSİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.

- American Diabetes Association, San Francisco, United States Of America, 13 - 17 June 2014, vol.63
- CLXXIV. **Constitution of Pre-diabetic State in C57BL6J Mice Versus Sprague Dawley Rats**
EKŞİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
American Diabetes Association, San Francisco, United States Of America, 13 - 17 June 2014, vol.63
- CLXXV. **Restoration of Pancreatic Beta Cell Mass and Function by GLP-1 Gene Delivery for Diabetes**
ŞANLIOĞLU S.
Beta Cells in Health and Disease, Kocaeli, Turkey, 21 - 23 May 2014, pp.1
- CLXXVI. **Diyabet hastalığına karşı geliştirilen insan vazoaktif intestinal peptid kodlayan HIV tabanlı gen transfer vektörlerinin yapımı ve testi**
ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKŞİ Y. E.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.12
- CLXXVII. **C57BL6J FARELER DİYETLE SPRAGUE DAWLEY SİÇANLARA KIYASLA DAHA HIZLI VE ETKİN PREDİYABET GELİŞİMİ GÖSTERDİ**
EKŞİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.167
- CLXXVIII. **C57BL6J FARELERDE DİYABET İNDÜKSİYONU PANKreas KÖKENLİ GLP-1 SENTEZİNİ ARTTİRDİ**
BALIK O., TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.166
- CLXXIX. **Diyabet tedavisinde inkretin tabanlı gen transfer stratejilerinin yeri**
ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014
- CLXXX. **C57BL6J FARELER DİYETLE SPRAGUE DAWLEY SİÇANLARA KIYASLA DAHA HIZLI VE ETKİN PREDİYABET GELİŞİMİ GÖSTERDİ**
EKŞİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.167
- CLXXXI. **C57BL6J FARELERDE DİYABET İNDÜKSİYONU PANKreas KÖKENLİ GLP-1 SENTEZİNİ ARTTİRDİ**
BALIK O., TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.166
- CLXXXII. **C57BL6J FARELER DİYETLE SPRAGUE DAWLEY SİÇANLARA KIYASLA DAHA HIZLI VE ETKİN PREDİYABET GELİŞİMİ GÖSTERDİ**
EKŞİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.167
- CLXXXIII. **C57BL6J FARELER DİYETLE SPRAGUE DAWLEY SİÇANLARA KIYASLA DAHA HIZLI VE ETKİN PREDİYABET GELİŞİMİ GÖSTERDİ**
EKŞİ Y. E., TAŞYÜREK M. H., Balık O., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.167
- CLXXXIV. **Diyabet Hastalığına Karşı Geliştirilen İnsan Vasoaktif İntestinal Peptid Kodlayan HIV tabanlı Gen Transfer Vektörlerinin Yapımı ve Testi**
TAŞYÜREK M. H., BALIK O., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.168
- CLXXXV. **C57BL6J FARELERDE DİYABET İNDÜKSİYONU PANKreas KÖKENLİ GLP-1 SENTEZİNİ ARTTİRDİ**
BALIK O., TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.166
- CLXXXVI. **Diyabet hastalığına karşı geliştirilen insan vazoaktif intestinal peptid kodlayan HIV tabanlı gen transfer vektörlerinin yapımı ve testi**
ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKŞİ Y. E.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.12
- CLXXXVII. **C57BL6J FARELERDE DİYABET İNDÜKSİYONU PANKreas KÖKENLİ GLP-1 SENTEZİNİ ARTTİRDİ**
BALIK O., TAŞYÜREK M. H., EKŞİ Y. E., ALTUNBAŞ H. A., BALCI M. K., ŞANLIOĞLU S.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.166
- CLXXXVIII. **Diyabet hastalığına karşı geliştirilen insan vazoaktif intestinal peptid kodlayan HIV tabanlı gen**

- transfer vektörlerinin yapımı ve testi**
ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKİŞİ Y. E.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.12
- CLXXXIX. Diyabet hastalığına karşı geliştirilen insan vazoaktif intestinal peptid kodlayan HIV tabanlı gen transfer vektörlerinin yapımı ve testi**
ŞANLIOĞLU S., ALTUNBAŞ H. A., BALCI M. K., TAŞYÜREK M. H., BALIK O., EKİŞİ Y. E.
50. Ulusal Diyabet Kongresi, Antalya, Turkey, 23 - 27 April 2014, pp.12
- CXC. GLP-1 and GLP-1-receptor expression profiles in pancreatic islets of Diet Induced Obese (DIO) Mice**
Tasyurek M. K., Hapıl F. Z., Altunbas H. A., CANATAN H., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish-Society-for-Gene-and-Cell-Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24
- CXCI. GLP-1 and GLP-1-receptor expression profiles in pancreatic islets of Diet Induced Obese (DIO) Mice**
TAŞYÜREK M. H., HAPİL F. Z., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish Society for Gene and Cell Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24, no.12, pp.138
- CXCII. Pancreatic expression profiles of vasoactive intestinal peptide and its receptors in mouse model of type 2 diabetes**
HAPİL F. Z., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish Society for Gene and Cell Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24, no.12, pp.138
- CXCIII. Pancreatic expression profiles of vasoactive intestinal peptide and its receptors in mouse model of type 2 diabetes**
HAPİL F. Z., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish Society for Gene and Cell Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24, no.12, pp.138
- CXCIV. Pancreatic expression profiles of vasoactive intestinal peptide and its receptors in mouse model of type 2 diabetes**
HAPİL F. Z., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish Society for Gene and Cell Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24, no.12, pp.138
- CXCV. GLP-1 and GLP-1-receptor expression profiles in pancreatic islets of Diet Induced Obese (DIO) Mice**
TAŞYÜREK M. H., HAPİL F. Z., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish Society for Gene and Cell Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24, no.12, pp.138
- CXCVI. Pancreatic expression profiles of vasoactive intestinal peptide and its receptors in mouse model of type 2 diabetes**
HAPİL F. Z., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish Society for Gene and Cell Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24, no.12, pp.138
- CXCVII. GLP-1 and GLP-1-receptor expression profiles in pancreatic islets of Diet Induced Obese (DIO) Mice**
TAŞYÜREK M. H., HAPİL F. Z., ALTUNBAŞ H. A., CANATAN H., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy and the Spanish Society for Gene and Cell Therapy, Madrid, Spain, 25 - 28 October 2013, vol.24, no.12, pp.138
- CXCVIII. Downregulation of Vasoactive Intestinal Peptide Expression in Type 2 Diabetes**
HAPİL F. Z., TAŞYÜREK M. H., GÜZEL N., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Congress of American Diabetes Association, Chicago, United States Of America, 21 - 25 June 2013, vol.62, pp.2258
- CXCIX. Downregulation of Vasoactive Intestinal Peptide Expression in Type 2 Diabetes**
HAPİL F. Z., TAŞYÜREK M. H., GÜZEL N., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Congress of American Diabetes Association, Chicago, United States Of America, 21 - 25 June 2013, vol.62, pp.2258
- CC. Downregulation of Vasoactive Intestinal Peptide Expression in Type 2 Diabetes**
HAPİL F. Z., TAŞYÜREK M. H., GÜZEL N., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.

- Congress of American Diabetes Association, Chicago, United States Of America, 21 - 25 June 2013, vol.62, pp.2258
- CCI. **Tip 2 diyabet deney hayvan modelinde diyabet induksiyonu adacıklarda vazoaktif intestinal peptid azalımıyla korelasyon gösterdi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., HAPİL F. Z., BALCI M. K., TAŞYÜREK M. H., GÜZEL N.
49. Ulusal Diyabet Kongresi, Antalya, Turkey, 17 - 21 April 2013, pp.20
- CCII. **Diyabette Vazoaktif Intestinal Peptidin terapotik rolü**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., ALTUNBAŞ H. A., BALCI M. K., Griffith T. S.
49. Ulusal Diyabet Kongresi, Antalya, Turkey, 17 - 21 April 2013, pp.12
- CCIII. **Tip 2 diyabet deney hayvan modelinde diyabet induksiyonu adacıklarda vazoaktif intestinal peptid azalımıyla korelasyon gösterdi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., HAPİL F. Z., BALCI M. K., TAŞYÜREK M. H., GÜZEL N.
49. Ulusal Diyabet Kongresi, Antalya, Turkey, 17 - 21 April 2013, pp.20
- CCIV. **Tip 2 diyabet deney hayvan modelinde diyabet induksiyonu adacıklarda vazoaktif intestinal peptid azalımıyla korelasyon gösterdi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., HAPİL F. Z., BALCI M. K., TAŞYÜREK M. H., GÜZEL N.
49. Ulusal Diyabet Kongresi, Antalya, Turkey, 17 - 21 April 2013, pp.20
- CCV. **Tip 2 diyabet deney hayvan modelinde diyabet induksiyonu adacıklarda vazoaktif intestinal peptid azalımıyla korelasyon gösterdi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., HAPİL F. Z., BALCI M. K., TAŞYÜREK M. H., GÜZEL N.
49. Ulusal Diyabet Kongresi, Antalya, Turkey, 17 - 21 April 2013, pp.20
- CCVI. **Diyabette Vazoaktif Intestinal Peptidin terapotik rolü**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., ALTUNBAŞ H. A., BALCI M. K., Griffith T. S.
49. Ulusal Diyabet Kongresi, Antalya, Turkey, 17 - 21 April 2013, pp.12
- CCVII. **Generation of a cost effective and a practical animal model for Type 2 Diabetes**
GÜZEL N., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European Society of Gene and Cell Therapy/French Society of Cell and Gene Therapy, Versailles, France, 25 - 29 October 2012, vol.23, no.10, pp.78-79
- CCVIII. **Generation of a cost effective and a practical animal model for Type 2 Diabetes**
GÜZEL N., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European Society of Gene and Cell Therapy/French Society of Cell and Gene Therapy, Versailles, France, 25 - 29 October 2012, vol.23, no.10, pp.78-79
- CCIX. **Generation of a cost effective and a practical animal model for Type 2 Diabetes**
GÜZEL N., TAŞYÜREK M. H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European Society of Gene and Cell Therapy/French Society of Cell and Gene Therapy, Versailles, France, 25 - 29 October 2012, vol.23, no.10, pp.78-79
- CCX. **Multiple Myeloma Patients Display Decreased Death Ligand Expression on T Lymphocytes.**
HAPİL F. Z., KÖKSOY S., ERSOY F. F., Kurtoğlu E., ÜNDAR L., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23, no.10
- CCXI. **Multiple Myeloma Patients Display Decreased Death Ligand Expression on T Lymphocytes.**
HAPİL F. Z., KÖKSOY S., ERSOY F. F., Kurtoğlu E., ÜNDAR L., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23, no.10
- CCXII. **Multiple Myeloma Patients Display Decreased Death Ligand Expression on T Lymphocytes.**
HAPİL F. Z., KÖKSOY S., ERSOY F. F., Kurtoğlu E., ÜNDAR L., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23, no.10
- CCXIII. **Multiple Myeloma Patients Display Decreased Death Ligand Expression on T Lymphocytes.**
HAPİL F. Z., KÖKSOY S., ERSOY F. F., Kurtoğlu E., ÜNDAR L., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23, no.10

- CCXIV. **Potential Therapeutic Role of Vasoactive Intestinal Peptide in Diabetes**
ŞANLIOĞLU A. D., Karacay B., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23
- CCXV. **Multiple Myeloma Patients Display Decreased Death Ligand Expression on T Lymphocytes**
Hapıl F. Z., KÖKSOY S., ERSOY F. F., KURTOĞLU E., ÜNDAR L., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23
- CCXVI. **Generation of a cost effective and a practical animal model for Type 2 Diabetes**
Guzel N., Tasyurek H., ŞANLIOĞLU A. D., BALCI M. K., ŞANLIOĞLU S.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23
- CCXVII. **Pancreatic acinar cells respond differentially to diabetic agents Streptozotocin and Cyclophosphamide**
KAHRAMAN S., Dirice E., ELPEK G. Ö., AYDIN C., BALCI M. K., OMER A., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, France, 25 - 29 October 2012, vol.23
- CCXVIII. **Decreased death ligand expression on T lymphocytes of multiple myeloma patients**
ŞANLIOĞLU S., hapıl f. z., KÖKSOY S., ÜNDAR L., ersoy f., kurtoğlu e.
Molecular Immunology & Immunogenetics Congress, Antalya, Turkey, 27 - 29 April 2012, pp.70
- CCXIX. **Decreased death ligand expression on T lymphocytes of multiple myeloma patients**
ŞANLIOĞLU S., hapıl f. z., KÖKSOY S., ÜNDAR L., ersoy f., kurtoğlu e.
Molecular Immunology & Immunogenetics Congress, Antalya, Turkey, 27 - 29 April 2012, pp.70
- CCXX. **The efficacy of insulin gene therapy in autoimmune diabetes**
ŞANLIOĞLU S.
Molecular Immunology & Immunogenetics Congress, Antalya, Turkey, 27 - 29 April 2012, pp.49-50
- CCXXI. **Apoptoz yoluyla deneysel adacık naklinde hucresel immun sistemi bertaraf edebilen yeni bir strateji**
ŞANLIOĞLU S.
Hücre ölümü araştırma teknikleri kongresi, İzmir, Turkey, 24 - 25 November 2011, pp.43
- CCXXII. **Death Ligand Expression Profiles on Cytotoxic Lymphocytes of Multiple Myeloma Patients**
ŞANLIOĞLU S., HAPİL F. Z., ÜNDAR L., GÜZEL N., KÖKSOY S., SALİM O.
XII Ulusal Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 27 - 30 October 2011, pp.109
- CCXXIII. **Death Ligand Expression Profiles on Cytotoxic Lymphocytes of Multiple Myeloma Patients**
ŞANLIOĞLU S., HAPİL F. Z., ÜNDAR L., GÜZEL N., KÖKSOY S., SALİM O.
XII Ulusal Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 27 - 30 October 2011, pp.109
- CCXXIV. **Rexin G, the first and the only targetted gene delivery vehicle developed to seek out and destroy metastatic cancer cell to date**
HAPİL F. Z., ŞANLIOĞLU S.
XII Ulusal Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 27 - 30 October 2011, pp.15
- CCXXV. **NOD farelerde streptozotosin veya siklofosfamid ile hızlandırılmış Tip 1 Diyabet gelişim sürecinde pankreatik asınar hucrelerde farklı TRAIL ligand ve reseptör paternleri**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., aydın ç., Dirice E., ELPEK G. Ö., BALCI M. K., KAHRAMAN S.
XII Ulusal Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 27 - 30 October 2011, pp.187
- CCXXVI. **Rexin G, the first and the only targetted gene delivery vehicle developed to seek out and destroy metastatic cancer cell to date**
HAPİL F. Z., ŞANLIOĞLU S.
XII Ulusal Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 27 - 30 October 2011, pp.15
- CCXXVII. **Death Ligand Expression Profiles on Cytotoxic Lymphocytes of Multiple Myeloma Patients**
ŞANLIOĞLU S., HAPİL F. Z., ÜNDAR L., GÜZEL N., KÖKSOY S., SALİM O.
XII Ulusal Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 27 - 30 October 2011, pp.109
- CCXXVIII. **NOD farelerde streptozotosin veya siklofosfamid ile hızlandırılmış Tip 1 Diyabet gelişim sürecinde**

- pankreatik asınar hucrelerde farklı TRAIL ligand ve reseptör paternleri**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., aydın ç., Dirice E., ELPEK G. Ö., BALCI M. K., KAHRAMAN S.
XII Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 27 - 30 October 2011, pp.187
- CCXXIX. Tip 1 Diyabette gen ve hucre tedavisinin yeri**
ŞANLIOĞLU S.
Turkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Antalya, Turkey, 12 - 16 October 2011, pp.33
- CCXXX. Efficacy of clinical gene and cell therapy in ADA SCID patients**
ŞANLIOĞLU S., Bişgin A.
9th National Medical Genetics Congress, İstanbul, Turkey, 1 - 05 December 2010, pp.128
- CCXXXI. Clinical genetic significance of TRAIL and TRAIL receptors in patients with head and neck cancer**
ŞANLIOĞLU S., YOLDAŞ ÇELİKTEM Ş. B., Özer Ç., Özen O.
9th National Medical Genetics Congress, İstanbul, Turkey, 1 - 05 December 2010, pp.59
- CCXXXII. "In Vivo Fluorescence Tracing Of Xenogeneic Islet Graft Survival In Type 1 Diabetes**
Kahraman Dirice S., Dirice E., ERTOSUN M. G., HAPİL F. Z., ÖZTÜRK S., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
9th National Congress of Medical Genetics, İstanbul, Turkey, 1 - 05 December 2010, vol.0, no.0, pp.1-2
- CCXXXIII. A novel combinatorial gene therapy modality successfully destroyed synoviocytes of patients with rheumatoid arthritis**
ŞANLIOĞLU S., YAZISIZ V., Bişgin A.
9th National Medical Genetics Congress, İstanbul, Turkey, 1 - 05 December 2010, pp.128
- CCXXXIV. Clinical genetic significance of TRAIL and TRAIL receptors in patients with head and neck cancer**
ŞANLIOĞLU S., YOLDAŞ ÇELİKTEM Ş. B., Özer Ç., Özen O.
9th National Medical Genetics Congress, İstanbul, Turkey, 1 - 05 December 2010, pp.59
- CCXXXV. In vivo fluorescence tracing of xenogeneic islet graft survival in Type 1 Diabetes**
ŞANLIOĞLU S., Kahraman S., Dirice E., Hapil F. Z.
9th National Medical Genetics Congress, İstanbul, Turkey, 1 - 05 December 2010, pp.129
- CCXXXVI. In vivo tracing of the most commonly used gene therapy vector**
ŞANLIOĞLU S., Kahraman S., Dirice E., ŞANLIOĞLU A. D.
9th National Medical Genetics Congress, İstanbul, Turkey, 1 - 05 December 2010, pp.128
- CCXXXVII. TRAIL profile of synoviocytes and peripheral blood lymphocytes of rheumatoid arthritis patients.**
Bisgin A., ŞANLIOĞLU A. D., Yoldas B., Aydin C., YAZISIZ V., TÜZÜNER S., Gorczynski R. M., Akdis C. A., Terzioglu E., ŞANLIOĞLU S.
XVIII Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), Milan, Italy, 22 - 25 October 2010, vol.21, pp.1358-1396
- CCXXXVIII. Endometrial hyperplasia features distinctive trail and trail receptor expression profiles**
AYDIN C., BİSGİN A., SANLIOĞLU A. D., PESTERELİ E., ERDOĞAN G., ÖZBUDAK İ. H., SIMSEK T., SANLIOĞLU S.
18th Annual Congress of the European Society of Gene and Cell Therapy, Milan, Italy, 22 - 25 October 2010, pp.1462-1463
- CCXXXIX. In vivo fluorescence imaging of xenogeneic islet graft survival**
KAHRAMAN S., DİRİCE E., HAPİL F. Z., ERTOSUN M. G., ÖZTÜRK S., GRIFFITH T. S., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
18th Annual Congress of the European Society of Gene and Cell Therapy, Milan, Italy, 22 - 25 October 2010, pp.1451
- CCXL. TRAIL profile of synoviocytes and peripheral blood lymphocytes of rheumatoid arthritis patients.**
Bisgin A., ŞANLIOĞLU A. D., Yoldas B., Aydin C., YAZISIZ V., TÜZÜNER S., Gorczynski R. M., Akdis C. A., Terzioglu E., ŞANLIOĞLU S.
XVIII Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), Milan, Italy, 22 - 25 October 2010, vol.21, pp.1358-1396
- CCXLI. In vivo fluorescence imaging of xenogeneic islet graft survival**
KAHRAMAN S., DİRİCE E., HAPİL F. Z., ERTOSUN M. G., ÖZTÜRK S., GRIFFITH T. S., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
18th Annual Congress of the European Society of Gene and Cell Therapy, Milan, Italy, 22 - 25 October 2010, pp.1451
- CCXLII. Spontaneous type 1 diabetes in NOD mice is related to an increase in DcR1 expression**

KAHRAMAN S., Dirice E., Elpek O., Ertosun M. G., BALCI M. K., OMER A., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1447-1448

- CCXLIII. **The importance of sTRAIL in patients with rheumatoid arthritis**
BISGIN A., Terzioglu E., ERBASAN F., AYDIN C., Sanlioglu S.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1461
- CCXLIV. **Trail profile of synoviocytes and peripheral blood lymphocytes of rheumatoid arthritis patients**
BISGIN A., Sanlioglu A. D., Yoldas B., AYDIN C., YAZISIZ V., TUZUNER S., Gorczynski R. M., AKDIS C. A., Terzioglu E., Sanlioglu S.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1448-1449
- CCXLV. **Distinctive expression profiles of trail and trail receptors in patients with endometrial carcinoma**
AYDIN C., BISGIN A., Sanlioglu A. D., Pestereli E., Erdogan G., Ozbudak I. H., ŞİMŞEK T., Sanlioglu S.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1462
- CCXLVI. **Endometrial hyperplasia features distinctive trail and trail receptor expression profiles**
AYDIN C., BISGIN A., Sanlioglu A. D., Pestereli E., Erdogan G., Ozbudak I. H., Simsek T., Sanlioglu S.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1462-1463
- CCXLVII. **The outcome of trail presentation on T cells in patients with multiple myeloma**
Hapil F. Z., BISGIN A., AYDIN C., ÜNDAR L., Sanlioglu A. D., Sanlioglu S.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1462
- CCXLVIII. **TRAIL expression significantly decreases in CY-accelerated type 1 diabetes in NOD mice**
KAHRAMAN S., DİRİCE E., Elpek O., Balci M. K., OMER A., Sanlioglu S., Sanlioglu A. D.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1453-1454
- CCXLIX. **STZ administration leads to a significant rise in TRAIL and DcR1 levels in Non-Obese Diabetic (NOD)**
DİRİCE E., KAHRAMAN S., Elpek O., Balci M. K., OMER A., Sanlioglu S., Sanlioglu A. D.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1453
- CCL. **In vivo fluorescence imaging of xenogeneic islet graft survival**
KAHRAMAN S., Dirice E., Hapil F. Z., Ertosun M. G., ÖZTÜRK S., Griffith T. S., ŞANLIOĞLU S., ŞANLIOĞLU A. D.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, Italy, 22 - 25 October 2010,
vol.21, pp.1451
- CCLI. **Allojenik ve xenogenenik pankreatik adacık transplantasyon başarısının in-vivo floresan görüntülemeyle takibi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Dirice E., HAPİL F. Z., KAHRAMAN S., Griffith T. S.
46. Ulusal Diyabet Kongresi, Antalya, Turkey, 12 - 16 May 2010, pp.5
- CCLII. **Allojenik ve xenogenenik pankreatik adacık transplantasyon başarısının in-vivo floresan görüntülemeyle takibi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Dirice E., HAPİL F. Z., KAHRAMAN S., Griffith T. S.
46. Ulusal Diyabet Kongresi, Antalya, Turkey, 12 - 16 May 2010, pp.5
- CCLIII. **Non-obese diabetic (NOD) farelerde streptozotosin veya siklofosfamid ile indüklenen diyabette T1D'in moleküler patogenezinin aydınlatılmasına yönelik bulgular**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., aydin ç., Dirice E., ELPEK G. Ö., BALCI M. K., KAHRAMAN S.
46. Ulusal Diyabet Kongresi, Antalya, Turkey, 12 - 16 May 2010, pp.6
- CCLIV. **Non-obese diabetic (NOD) farelerde streptozotosin veya siklofosfamid ile indüklenen diyabette T1D'in moleküler patogenezinin aydınlatılmasına yönelik bulgular**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., aydin ç., Dirice E., ELPEK G. Ö., BALCI M. K., KAHRAMAN S.

46. Ulusal Diyabet Kongresi, Antalya, Turkey, 12 - 16 May 2010, pp.6
- CCLV. "In vivo Floresan Görüntüleme Yöntemiyle Xenojenik Pankreatik Adacık Trandplantasyon Başarısının ve Sağkalımının Takibi
Kahraman Dirice S., ERTOSUN M. G., HAPİL F. Z., ÖZTÜRK S., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
2nd National Congress of Pamukkale University Medical School, Denizli, Turkey, 9 - 11 April 2010, vol.0, no.0, pp.1-2
- CCLVI. In vivo fluorescence imagining as a method to assess pancreatic islet xenograft failure
KAHRAMAN DİRİCE S., HAPİL ZEVKLİLER F. Z., ERTOSUN M. G., DİRİCE E., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
ESGCT (The European Society of Gene and Cell Therapy) 2009, Hannover, Germany, 21 - 25 November 2009
- CCLVII. TRAIL death receptor-4 and decoy receptors expression on CD8+T cells correlate with the disease severity in rheumatoid arthritis patients p.149, Nov 21-25, 2009, 2009 Hannover, Germany. Human Gene Therapy 2009; 20 (11): 1471-1471
Bisgin A., Terzioglu E., Aydin C., YAZISIZ V., BALCI N., BAĞCI H., Gorczynski R. M., Akdis C. A., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research,, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1471
- CCLVIII. Adenovirus mediated TRAIL gene therapy approach provides sustained insulin expression in STZ-induced diabetic rats
DİRİCE E., ŞANLIOĞLU A. D., KAHRAMAN S., ÖZTÜRK S., BALCI M. K., ÖMER A., GRIFFITH T. S., ŞANLIOĞLU S.
17th Annual Congress of the European Society of Gene & Cell Therapy, Hannover, Germany, 21 - 25 November 2009, pp.1471-1472
- CCLIX. Adenovirus mediated TRAIL gene therapy approach provides sustained insulin expression in STZ-induced diabetic rats
DİRİCE E., ŞANLIOĞLU A. D., KAHRAMAN S., ÖZTÜRK S., BALCI M. K., ÖMER A., GRIFFITH T. S., ŞANLIOĞLU S.
17th Annual Congress of the European Society of Gene & Cell Therapy, Hannover, Germany, 21 - 25 November 2009, pp.1471-1472
- CCLX. Tracing of the fate of allogeneic islet grafts via CCD camera
KAHRAMAN S., Hapıl F. Z., AYDIN C., BISGIN A., Dirice E., Griffith T. S., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1479
- CCLXI. Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients
BISGIN A., KARGI A., YALCIN A., AYDIN C., SAVAS B., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1417
- CCLXII. Diagnostic significance of serum sTRAIL in rheumatoid arthritis
BISGIN A., AYDIN C., ERBASAN F., Terzioglu E., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1494
- CCLXIII. Prospective cell and gene therapy approaches designed to extend islet graft survival in patients with type 1 diabetes
ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1482-1483
- CCLXIV. Adenovirus mediated TRAIL gene therapy approach provides sustained insulin expression in STZ-induced diabetic rats
DIRICE E., Sanlioglu A. D., KAHRAMAN S., ÖZTÜRK S., Balci M., Omer A., Griffith T., Sanlioglu S.

- Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1471-1472
- CCLXV. **Alterations in TRAIL ligand and receptor expression profiles in CY-accelerated type 1 diabetes in NOD mice**
Sanlioglu A. D., KAHRAMAN S., Dirice E., ELPEK O., Balci M., OMER A., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1483
- CCLXVI. **In vivo fluorescence imaging as a method to assess pancreatic islet xenograft failure**
KAHRAMAN S., Hapil F. Z., ERTOSUN M. G., Dirice E., ŞANLIOĞLU A. D., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1479
- CCLXVII. **TRAIL death receptor-4 and decoy receptors expression on CD8+T cells correlate with the disease severity in rheumatoid arthritis patients**
BISGIN A., Terzioglu E., AYDIN C., YAZISIZ V., BALCI N., Bagci H., Gorczynski R., AKDIS C., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1471
- CCLXVIII. **Monitoring of systemic delivery of adenovirus mediated EGFP transgene expression in mice using fluorescence imaging**
KAHRAMAN S., Dirice E., Sanlioglu A. D., Yoldas B., Bagci H., ERKILIÇ M., Griffith T., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1507
- CCLXIX. **Differential levels of TRAIL ligand and receptor expressions in STZ-induced T1 diabetes in non-obese diabetic (NOD) mice**
ŞANLIOĞLU A. D., Dirice E., KAHRAMAN S., ELPEK O., Balci M., OMER A., ŞANLIOĞLU S.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1483
- CCLXX. **Distinctive expression profile of TRAIL and TRAIL receptors in patients with head and neck cancer**
Yoldas B., Ozer C., Ozen O., Canpolat T., Dogan I., ŞANLIOĞLU S., Ozluoglu L.
Combined Meeting of the 17th European-Society-of-Gene-and-Cell-Therapy/16th German-Society-for-Gene-Therapy/4th German-Society-for-Stem-Cell-Research, Hannover, Germany, 21 - 25 November 2009, vol.20, pp.1422-1423
- CCLXXI. **Romatoid Artrit hastalarının tanısında serum s-TRAIL'in önemi**
BİŞGİN A., AYDIN Ç., ERBASAN F., TERZİOĞLU M. E., ŞANLIOĞLU S.
X. Ulusal Romatoloji Kongresi, Turkey, 30 October - 03 November 2009
- CCLXXII. **Romatoid artritte CD8+ T hücrelerindeki TRAIL Ligand ve reseptör profilinin hastalık seyri ile ilişkisi, OP.018, Belek, Antalya, Turkey, 2009.**
Bisgin A., TERZİOĞLU M. E., Aydin C., YAZISIZ V., BALCI N., BAĞCI H., Akdis C. A., Gorczynski R. M., ŞANLIOĞLU S.
X. Ulusal Romatoloji Kongresi, Antalya, Turkey, 30 October - 03 November 2009, pp.18
- CCLXXIII. **Sistemik adenovirus aracılı gen nakli in vivo olarak CCD kameralar ile başarıyla görüntülenebilir**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Dirice E., BAĞCI H., ERKILIÇ M., KAHRAMAN S., YOLDAŞ ÇELİKTEM Ş. B., Griffith T. S.
XI Ulusal Tibbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 28 - 31 October 2009, pp.32
- CCLXXIV. **Ex vivo adenovirus aracılı EGFP gen aktarımı yapılan pankreatik adacık ksenotransplantasyon başarısı CCD kamera ile belirlendi**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., HAPİL F. Z., BALCI M. K., KAHRAMAN S., Griffith T. S.

- XI Ulusal Tibbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 28 - 31 October 2009, pp.39
- CCLXXV. **TRAİL ve reseptörlerinin yassı hücreli larenks ve oral kavite kanserleriyle ilişkisi**
ŞANLIOĞLU S., OZER C., DOGAN I., OZLUOGLU L. N., YOLDAŞ ÇELİKTEN Ş. B., CANPOLAT T.
31. Ulusal Kulak Burun Bogaz ve Bas ve Boyun Cerrahisi Kongresi, Antalya, Turkey, 28 October - 01 November 2009, pp.34
- CCLXXVI. **Sistemik adenovirus aracılı gen nakli in vivo olarak CCD kameralar ile başarıyla görüntülenebilir**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Dirice E., BAĞCI H., ERKILIÇ M., KAHRAMAN S., YOLDAŞ ÇELİKTEN Ş. B., Griffith T. S.
XI Ulusal Tibbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 28 - 31 October 2009, pp.32
- CCLXXVII. **TRAİL ve reseptörlerinin yassı hücreli larenks ve oral kavite kanserleriyle ilişkisi**
ŞANLIOĞLU S., OZER C., DOGAN I., OZLUOGLU L. N., YOLDAŞ ÇELİKTEN Ş. B., CANPOLAT T.
31. Ulusal Kulak Burun Bogaz ve Bas ve Boyun Cerrahisi Kongresi, Antalya, Turkey, 28 October - 01 November 2009, pp.34
- CCLXXVIII. **Ex vivo adenovirus aracılı EGFP gen aktarımı yapılan pankreatik adacık ksenotransplantasyon başarısı CCD kamera ile belirlendi**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., HAPİL F. Z., BALCI M. K., KAHRAMAN S., Griffith T. S.
XI Ulusal Tibbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 28 - 31 October 2009, pp.39
- CCLXXIX. **Serum sTRAIL konsantrasyonunun romatoid artrit tanısındaki yeri**
ŞANLIOĞLU S., BISGIN A., aydın ç., ERBASAN F., TERZİOĞLU M. E.
XI Ulusal Tibbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 28 - 31 October 2009, pp.145
- CCLXXX. **Ex vivo adenovirus aracılı EGFP gen aktarımı yapılan pankreatik adacık ksenotransplantasyon başarısı CCD kamera ile belirlendi**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., HAPİL F. Z., BALCI M. K., KAHRAMAN S., Griffith T. S.
XI Ulusal Tibbi Biyoloji ve Genetik Kongresi, Muğla, Turkey, 28 - 31 October 2009, pp.39
- CCLXXXI. **Rheumatoid Arthritis disease activity is correlated with TRAIL death receptor-4 and decoy receptor expresions on CD8+ T cells. Jul 04-09, 2009. FEBS JOURNAL 2009; 276 (Supp 1):259**
Bisgin A., Terzioglu E., Aydin C., YAZISIZ V., BALCI N., BAĞCI H., Gorczynski R. M., Akdis C. A., ŞANLIOĞLU S.
34th Congress of the Federation-of-European-Biochemical-Societies,, Prague,, Czech Republic, 4 - 09 July 2009, vol.1, pp.276
- CCLXXXII. **Rheumatoid arthritis disease activity is correlated with TRAIL death receptor-4 and decoy receptors expression on CD8+ T cells**
ŞANLIOĞLU S., BISGIN A., AKDIS C., BAĞCI H., TERZİOĞLU M. E., BALCI N., GORCZYNSKI R. M., YAZISIZ V.
34th FEBS Congress, Prag, Czech Republic, 4 - 09 July 2009, pp.6
- CCLXXXIII. **Rheumatoid Arthritis disease activity is correlated with TRAIL death receptor-4 and decoy receptor expresions on CD8+T cells**
Bisgin A., TERZİOĞLU M. E., Aydin C., YAZISIZ V., BALCI N., Bagci H., Gorczynski R. M., Akdis C. A., ŞANLIOĞLU S.
34th Congress of the Federation-of-European-Biochemical-Societies, Prague, Czech Republic, 4 - 09 July 2009, vol.276, pp.259
- CCLXXXIV. **Increased serum sTRAIL level following BevacizumAb treatment is correlated with patient survival in metastatic colon cancer**
BISGIN A., AYDIN C., Terzioglu E., YALÇIN A. N., KARGI A., SAVAS B., ŞANLIOĞLU S.
34th Congress of the Federation-of-European-Biochemical-Societies, Prague, Czech Republic, 4 - 09 July 2009, vol.276, pp.301-302
- CCLXXXV. **CD8+ T cell associated TRAIL DR4 death and DcR1, DcR2 decoy receptors expression correlate with disease severity in patients with rheumatoid arthritis**
ŞANLIOĞLU S., Bişgin A., TERZİOĞLU M. E., aydın ç., YAZISIZ V., BALCI N., BAĞCI H., Gorczynski R., Akdis C.
FRI-0065, Copenhagen, Denmark, 10 - 13 June 2009, pp.6
- CCLXXXVI. **CD8+ T cell associated TRAIL DR4 death ligand and decoy receptor expressions correlate with disease severity in patients with rheumatoid arthritis. p.FRI0065, 10-13 June 2009, Copenhagen, Ann Rheum Dis 2009; 68(Suppl3):380.**
Bisgin A., Terzioglu E., Aydin C., YAZISIZ V., Erbasan F., BALCI N., BAĞCI H., Gorczynski R. M., Akdis C. A., ŞANLIOĞLU

- S.
Annual European Congress of Rheumatology,, Copenhagen, Denmark, 10 - 13 June 2009, vol.68, pp.380
- CLXXXVII. **Serum s TRAIL us efor the assessment of the efficacy of BevacizumAb treatment in metastatic colon cancer**
ŞANLIOĞLU S., Bişgin A., Yalçın A., aydın ç., ekinci d., TERZİOĞLU M. E., Savaş B.
1st International Multidisciplinary Cancer Research Congress, Antalya, Turkey, 21 - 24 May 2009, pp.8
- LXXXVIII. **Tip 1 diyabette alloimmune mononüklear hücre infiltrasyonun gen tedavisiyle baskınlaması fonksiyonel adacık-graft ömrünü uzatır**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., Griffith T. S.
45. Ulusal Diyabet Kongresi, Antalya, Turkey, 20 - 24 May 2009, pp.56
- CCLXXXIX. **Tip 1 diyabette alloimmune mononüklear hücre infiltrasyonun gen tedavisiyle baskınlaması fonksiyonel adacık-graft ömrünü uzatır**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., Griffith T. S.
45. Ulusal Diyabet Kongresi, Antalya, Turkey, 20 - 24 May 2009, pp.56
- CCXC. **Diyabetik farelere sıçan pankreatik adacıklarının ksenotransplantasyonu normoglisemi sağlamaktadır**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
45. Ulusal Diyabet Kongresi, Antalya, Turkey, 20 - 24 May 2009, pp.76
- CCXCI. **Diyabetik farelere sıçan pankreatik adacıklarının ksenotransplantasyonu normoglisemi sağlamaktadır**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
45. Ulusal Diyabet Kongresi, Antalya, Turkey, 20 - 24 May 2009, pp.76
- CCXCII. **Molecular profile of tumor necrosis factor-related apoptosis inducing ligand (trail) and its receptors on T cells in patients with rheumatoid arthritis.** p.13, May 5-8, 2009, İstanbul, Turkey; IUBMB Life, 61, 327, (2009).
Bisgin A., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
Turkish Society of Molecular Medicine. Third International Congress of Molecular Medicine,, İstanbul, Turkey, 5 - 08 May 2009, vol.61, pp.327
- CCXCIII. **Highlights in the molecular pathogenesis of type 1 diabetes**
ŞANLIOĞLU S., Kahraman S., Dirice E., Elpek O., BALCI M. K., Ömer A.
3rd International Congress of Molecular Medicine, İstanbul, Turkey, 5 - 08 May 2009, pp.324-325
- CCXCIV. **Molecular profile of tumor necrosis factor-related apoptosis inducing ligand (trail) and its receptors on T cells in patients with rheumatoid arthritis.** p.13, May 5-8, 2009, İstanbul, Turkey; IUBMB Life, 61, 327, (2009).
Bisgin A., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
Turkish Society of Molecular Medicine. Third International Congress of Molecular Medicine,, İstanbul, Turkey, 5 - 08 May 2009, vol.61, pp.327
- CCXCV. **Highlights in the molecular pathogenesis of type 1 diabetes**
ŞANLIOĞLU S., Kahraman S., Dirice E., Elpek O., BALCI M. K., Ömer A.
3rd International Congress of Molecular Medicine, İstanbul, Turkey, 5 - 08 May 2009, pp.324-325
- CCXCVI. **Comparative molecular analysis of TRAIL ligand and receptor expression profiles in cyclophosphamide versus streptozotocin-induced diabetes in non-obese diabetic (NOD) mice**
ŞANLIOĞLU S., Kahraman S., Dirice E., ELPEK G. Ö., BALCI M. K., ömer a.
11th European Congress of Endocrinology, İstanbul, Turkey, 25 - 29 April 2009, pp.336
- CCXCVII. **A novel gene therapy strategy involving immune-modulation relinquished lymphocyte infiltration into islet grafted sites in STZ induced diabetic rats**
ŞANLIOĞLU S., Dirice E., ŞANLIOĞLU A. D., Kahraman S., Ömer A., BALCI M. K., Griffith T.
11th European Congress of Endocrinology, İstanbul, Turkey, 25 - 29 April 2009, pp.1
- CCXCVIII. **Comparative molecular analysis of TRAIL ligand and receptor expression profiles in cyclophosphamide versus streptozotocin-induced diabetes in non-obese diabetic (NOD) mice**
ŞANLIOĞLU S., Kahraman S., Dirice E., ELPEK G. Ö., BALCI M. K., ömer a.

- 11th European Congress of Endocrinology, İstanbul, Turkey, 25 - 29 April 2009, pp.336
- CCXCIX. **A novel gene therapy strategy involving immune-modulation relinquished lymphocyte infiltration into islet grafted sites in STZ induced diabetic rats**
ŞANLIOĞLU S., Dirice E., ŞANLIOĞLU A. D., Kahraman S., Ömer A., BALCI M. K., Griffith T.
11th European Congress of Endocrinology, İstanbul, Turkey, 25 - 29 April 2009, pp.1
- CCC. **BevacizumAb tedavisi uygulanan kolon kanserli hastalarda sTRAIL düzeyinin artışı sağ kalım süresi ile ilişkilidir**
ŞANLIOĞLU S., YALCIN A. D., BISGIN A., KARGI A., SAVAS B., aydın ç., EKINCI D., TERZİOĞLU M. E.
XVIII. Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 26 April 2009, pp.410
- CCCI. **The potential use of TRAIL and its receptor expression profile as markers to monitor the prognosis of patients with rheumatoid arthritis**
ŞANLIOĞLU S., Bişgin A., TERZİOĞLU M. E., YAZISIZ V., BALCI M. K., BAĞCI H., Gorczynski R., Akdis C.
World Immune Regulation Meeting-III, Davos, Swaziland, 22 - 25 March 2009, pp.104
- CCCII. **The potential use of TRAIL and its receptor expression profile as markers to monitor the prognosis of patients with rheumatoid arthritis. Abstract. P104. P.104, 22-25 March 2009, Davos, Switzerland.**
Bisgin A., Terzioglu E., YAZISIZ V., BALCI N., BAĞCI H., Gorczynski R. M., Akdis C. A., ŞANLIOĞLU S.
World Immune Regulation Meeting-III, Davos, Switzerland, 22 - 25 March 2009, vol.1, pp.104
- CCCIII. **The potential use of TRAIL and its receptor expression profile as markers to monitor the prognosis of patients with rheumatoid arthritis**
ŞANLIOĞLU S., Bişgin A., TERZİOĞLU M. E., YAZISIZ V., BALCI M. K., BAĞCI H., Gorczynski R., Akdis C.
World Immune Regulation Meeting-III, Davos, Swaziland, 22 - 25 March 2009, pp.104
- CCCIV. **Pancreatic ductal adenocarcinoma (PDAC) patients reveal elevated TRAIL Death Receptor-4 (DR4) and decoy receptor-2 (DcR2) expression correlated with significant cell death**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., ÖZDOĞAN M., SÜLEYMANLAR İ., BALCI M. K., GRIFFITH T., ŞANLIOĞLU S.
XVIth Annual Congress of the European Society of Gene and Cell Therapy, Brüksel, Belgium, 13 - 16 November 2008, pp.1104
- CCCV. **Clinical significance of TRAIL and its receptor expression profiles on CD4+ CD25+ Foxp3+ Tregs and CD8+CD25+ T cells in patients with rheumatoid arthritis. p.134, Brugge, Belgium, 13-16 November 2008. Abstract; Human Gene Therapy 19:1098-1202 (P134), October 2008.**
Bisgin A., Ulker M., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
XVth Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), Brugge, Belgium, 13 - 16 November 2008, vol.19, pp.1098-1202
- CCCVI. **Soluble TRAIL concentrations in patients with rheumatoid arthritis. p.135, Brugge, Belgium, 13-16 November 2008. Abstract; Human Gene Therapy 19: 1149, October 2008.**
Bisgin A., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
XVth Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), Brugge, Belgium, 13 - 16 October 2008, vol.19, pp.1149
- CCCVII. **Clinical significance of TRAIL and its receptor expression profiles on CD4+CD25+Foxp3+Tregs and CD8+CD25+T cells in patients with rheumatoid arthritis**
BISGIN A., YAZISIZ V., ULKER M., Terzioglu E., ŞANLIOĞLU S.
16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belgium, 13 - 16 November 2008, vol.19, pp.1148-1149
- CCCVIII. **In vivo imaging to detect the duration of adenovirus mediated EGFP transgene expression in allogeneic islet grafts**
KAHRAMAN S., DIRICE E., ŞANLIOĞLU A. D., BALCI M. K., Omer A., Griffith T., ŞANLIOĞLU S.
16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belgium, 13 - 16 November 2008, vol.19, pp.1121-1122
- CCCIX. **Prolonged normoglycemia in STZ-induced diabetic rats transplanted with Adenovirus-mediated human TRAIL gene (Ad5hTRAIL) infected islets**
DIRICE E., ŞANLIOĞLU A. D., KAHRAMAN S., Omer A., BALCI M. K., Griffith T. S., ŞANLIOĞLU S.

- 16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belgium, 13 - 16 November 2008, vol.19, pp.1119-1120
- CCCX. **Soluble TRAIL concentrations in patients with rheumatoid arthritis**
BİSGİN A., YAZISIZ V., Terzioglu E., ŞANLIOĞLU S.
16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belgium, 13 - 16 November 2008, vol.19, pp.1149
- CCCXI. **Pancreatic ductal adenocarcinoma (PDAC) patients reveal elevated TRAIL Death Receptor-4 (DR4) and decoy receptor-2 (DcR2) expression correlated with significant cell death**
ŞANLIOĞLU A. D., Dirice E., ELPEK G. Ö., Korcum A. F., Ozdogan M., SÜLEYMANLAR İ., BALCI M. K., Griffith T., ŞANLIOĞLU S.
16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belgium, 13 - 16 November 2008, vol.19, pp.1104
- CCCXII. **Pancreatic ductal adenocarcinoma (PDAC) patients reveal elevated TRAIL Death Receptor-4 (DR4) and decoy receptor-2 (DcR2) expression correlated with significant cell death**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., ÖZDOĞAN M., SÜLEYMANLAR İ., BALCI M. K., GRIFFITH T., ŞANLIOĞLU S.
XVIth Annual Congress of the European Society of Gene and Cell Therapy, Brüksel, Belgium, 10 September - 15 October 2008, pp.1104
- CCCXIII. **Pancreatic ductal adenocarcinoma (PDAC) patients reveal elevated TRAIL Death Receptor-4 (DR4) and decoy receptor-2 (DcR2) expression correlated with significant cell death**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., ÖZDOĞAN M., SÜLEYMANLAR İ., BALCI M. K., GRIFFITH T., ŞANLIOĞLU S.
XVIth Annual Congress of the European Society of Gene and Cell Therapy, Brüksel, Belgium, 10 September - 15 October 2008, pp.1104
- CCCXIV. **Pancreatic ductal adenocarcinoma (PDAC) patients reveal elevated TRAIL Death Receptor-4 (DR4) and decoy receptor-2 (DcR2) expression correlated with significant cell death**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., ÖZDOĞAN M., SÜLEYMANLAR İ., BALCI M. K., GRIFFITH T., ŞANLIOĞLU S.
XVIth Annual Congress of the European Society of Gene and Cell Therapy, Brüksel, Belgium, 10 September - 15 October 2008, pp.1104
- CCCXV. **Comparative analysis of TRAIL and its receptor expression profiles in synovites versus peripheral lymphocytes of patients with rheumatoid arthritis. June 2008, Paris, France. Ann Rheum Dis 2008;67(Suppl II):588.**
Bisgin A., ŞANLIOĞLU A. D., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
Annual European Congress of Rheumatology, Paris, France, 7 - 12 June 2008, vol.67, pp.588
- CCCXVI. **Comparative analysis of TRAIL and its receptor expression profiles in synovites versus peripheral lymphocytes of patients with rheumatoid arthritis. June 2008, Paris, France. Ann Rheum Dis 2008;67(Suppl II):588.**
Bisgin A., ŞANLIOĞLU A. D., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
Annual European Congress of Rheumatology, Paris, France, 7 - 12 June 2008, vol.67, pp.588
- CCCXVII. **Differential alteration of TRAIL and its receptor expression profiles in patients with pancreatic ductal adenocarcinoma**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., BALCI M. K., ÖMER A., GRIFFITH T., ŞANLIOĞLU S.
44th ASCO Annual Meeting, Chicago, United States Of America, 30 May - 03 June 2008, pp.663
- CCCXVIII. **Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with rheumatoid arthritis. Abstract No 14,**
Bisgin A., ŞANLIOĞLU A. D., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, vol.1, pp.1
- CCCXIX. **Adenovirus-mediated human TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets provides prolonged normoglycemia in STZ-induced diabetic rats**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.

3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 - 01 May 2008, pp.10
- CCCXX. **Gene therapy application scenarios to prolong islet-graft survival in patients with type 1 diabetes**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.5
- CCCXXI. **Pancreatic ductal adenocarcinoma (PDAC) patients displayed high levels of TRAIL death receptor-4 (DR4) and decoy receptor-2 (DCR2) expressions in connection with significant amount of cell death.**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., SÜLEYMANLAR İ., ÖZDOĞAN M., BALCI M. K., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.6
- CCCXXII. **Pancreatic ductal adenocarcinoma (PDAC) patients displayed high levels of TRAIL death receptor-4 (DR4) and decoy receptor-2 (DCR2) expressions in connection with significant amount of cell death**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., Özdoğan M., SÜLEYMANLAR İ., BALCI M. K., GRIFFITH T., ŞANLIOĞLU S.
3. Klinik Pratikte Kok Hücre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.60
- CCCXXIII. **In vivo fluorescent imaging of adenovirus delivery of reporter gene expression for allogeneic islet transplantation**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.11
- CCCXXIV. **Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with rheumatoid arthritis. Abstract No 14,**
Bisgin A., ŞANLIOĞLU A. D., YAZISIZ V., TERZİOĞLU M. E., ŞANLIOĞLU S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, vol.1, pp.1
- CCCXXV. **Gene therapy mediated apoptosis inducing approaches employing Ad5hTRAIL and a DCR2 siRNA strategy in lung cancer patients**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., AKDIS C., aydın ç., ÖZBİLİM G., DERTSİZ L., ÖZBUDAK Ö.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.3
- CCCXXVI. **Pancreatic ductal adenocarcinoma (PDAC) patients displayed high levels of TRAIL death receptor-4 (DR4) and decoy receptor-2 (DCR2) expressions in connection with significant amount of cell death.**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., SÜLEYMANLAR İ., ÖZDOĞAN M., BALCI M. K., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.6
- CCCXXVII. **The success of rat islet isolation mainly relies on complete pancreas inflation**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., YOLDAŞ ÇELİKTEMEN Ş. B., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.4
- CCCXXVIII. **Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with rheumatoid arthritis**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., BISGIN A., TERZİOĞLU M. E., YAZISIZ V.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.14
- CCCXXIX. **The success of rat islet isolation mainly relies on complete pancreas inflation**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., YOLDAŞ ÇELİKTEMEN Ş. B., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.4
- CCCXXX. **Adenovirus-mediated human TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets provides prolonged normoglycemia in STZ-induced diabetic rats**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 - 01 May 2008, pp.10
- CCCXXXI. **Gene therapy application scenarios to prolong islet-graft survival in patients with type 1 diabetes**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.5
- CCCXXXII. **In vivo fluorescent imaging of adenovirus delivery of reporter gene expression for allogeneic islet transplantation**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.

3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.11
- :CCXXXIII. **The success of rat islet isolation mainly relies on complete pancreas inflation**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., YOLDAŞ ÇELİKTEM Ş. B., Griffith T. S.
3. Klinik Pratikte Kok Hucre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 29 May - 01 June 2008, pp.4
- :CCXXXIV. **Pankreatik adacik izolasyon basarisini artirmaya yonelik yapılan deneysel bir calisma**
ŞANLIOĞLU S., Ömer A., Dirice E., BALCI M. K., KAHRAMAN S., YOLDAŞ ÇELİKTEM Ş. B., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.8
- CCCXXXV. **Pankreatik adaciklarda adenoviral vektor aracili transgen sentez suresinin in vivo olarak CCCD kamera ile goruntulenmesi**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.2
- :CCXXXVI. **Pankreatik adaciklara adenovirus aracili insan TRAIL geni (Ad5hTRAIL) aktarimi STZ induklemeli diyabetik sicanlarda uzun sureli normoglisemi saglar**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.1
- CCXXXVII. **Pankreatik adacik izolasyon basarisini artirmaya yonelik yapılan deneysel bir calisma**
ŞANLIOĞLU S., Ömer A., Dirice E., BALCI M. K., KAHRAMAN S., YOLDAŞ ÇELİKTEM Ş. B., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.8
- :CXXXVIII. **Tip 1 diyabet hastalarında gerceklestirilen adacik naklinde graft sagkalimini uzatabilecek gen tedavi senaryolari**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.3
- :CCXXXIX. **Pankreatik duktal adenokarsinomali hastalarda trail olum reseptoru-4 (DR4) ve yalancı reseptor-2'nin (DCR2) ekspresyonlarındaki artis, artan hucre olumları ile iliskilidir**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., SÜLEYMANLAR İ., OZDOGAN M., BALCI M. K., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.67
- CCCXL. **Pankreatik duktal adenokarsinomlu hastalarda trail ölüm reseptörü-4 (DR4) ve yalancı reseptor-2'nin (DCR2) ekspresyonlarındaki artis, artan hücre ölümleri ile iliskilidir**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., ÖZDOĞAN M., SÜLEYMANLAR İ., BALCI M. K., GRIFFITH T., ŞANLIOĞLU S.
44. ULUSAL DİYABET KONGRESİ, Antalya, Turkey, 28 May - 01 June 2008, pp.37
- CCCXLI. **Pankreatik duktal adenokarsinomlu hastalarda trail olum reseptoru-4 (DR4) ve yalancı reseptor-2'nin (DCR2) ekspresyonlarındaki artis, artan hucre olumları ile iliskilidir**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., SÜLEYMANLAR İ., OZDOGAN M., BALCI M. K., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.67
- CCCXLII. **Tip 1 diyabet hastalarında gerceklestirilen adacik naklinde graft sagkalimini uzatabilecek gen tedavi senaryolari**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.3
- CCCXLIII. **Pankreatik adaciklarda adenoviral vektor aracili transgen sentez suresinin in vivo olarak CCCD kamera ile goruntulenmesi**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.2
- CCCXLIV. **Pankreatik adaciklara adenovirus aracili insan TRAIL geni (Ad5hTRAIL) aktarimi STZ induklemeli diyabetik sicanlarda uzun sureli normoglisemi saglar**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KAHRAMAN S., Griffith T. S.
44. Ulusal Diyabet Kongresi, Antalya, Turkey, 28 May - 01 June 2008, pp.1
- CCCXLV. **TRAILING from molecular diagnostics to prostate cancer gene therapy**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., BALCI M. K., Griffith T. S.

- XIX Ulusal İmmunoloji Kongresi, Antalya, Turkey, 21 - 24 November 2007, pp.33
- CCCXLVI. **TRAILING from molecular diagnostics to prostate cancer gene therapy**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KÖKSAL İ. T., KARACAY B., ÇİFTÇİOĞLU M. A., LÜLECI G., BAYKARA M., Griffith T. S.
XIX Ulusal İmmunoloji Kongresi, Antalya, Turkey, 21 - 24 November 2007, pp.33
- CCCXLVII. **Comparative Analysis of TRAIL and Its Receptor Expression Profiles in Synoviocytes Versus Peripheral Lymphocytes of Patients with Rheumatoid Arthritis.** p.258, Rotterdam, The Netherlands, Abstract; Human Gene Therapy 18:994-1092, October 2007.
Bisgin A., ŞANLIOĞLU A. D., YAZISIZ V., Ulker M., TERZİOĞLU M. E., ŞANLIOĞLU S.
XVth Annual Congress of the European Society of Gene and Cell Therapy, Rotherdam, Netherlands, 27 - 30 October 2007, vol.18, pp.1092
- CCCXLVIII. **Comparative Analysis of TRAIL and Its Receptor Expression Profiles in Synoviocytes Versus Peripheral Lymphocytes of Patients with Rheumatoid Arthritis.** p.258, Rotterdam, The Netherlands, Abstract; Human Gene Therapy 18:994-1092, October 2007.
Bisgin A., ŞANLIOĞLU A. D., YAZISIZ V., Ulker M., TERZİOĞLU M. E., ŞANLIOĞLU S.
XVth Annual Congress of the European Society of Gene and Cell Therapy, Rotherdam, Netherlands, 27 - 30 October 2007, vol.18, pp.1092
- CCCXLIX. **Adenovirus vectors efficiently deliver TRAIL into pancreatic islets without generating cytotoxic effects**
DIRICE E., ŞANLIOĞLU A. D., Omer A., BALCI M. K., Griffith T., ŞANLIOĞLU S.
15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Rotterdam, Netherlands, 27 - 30 October 2007, vol.18, pp.1074
- CCCL. **High endogenous TRAIL expression levels in human pancreas is correlated with increased cell death**
ŞANLIOĞLU A. D., DIRICE E., Elpe O., Korcum A. F., BALCI M. K., Omer A., Griffith T., ŞANLIOĞLU S.
15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Rotterdam, Netherlands, 27 - 30 October 2007, vol.18, pp.1074-1075
- CCCLI. **Comparative analysis of TRAIL and its receptor expression profiles in synoviocytes versus peripheral lymphocytes of patients with rheumatoid arthritis**
BISGIN A., ŞANLIOĞLU A. D., YAZISIZ V., ULKER M., Terzioglu E., ŞANLIOĞLU S.
15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Rotterdam, Netherlands, 27 - 30 October 2007, vol.18, pp.1091-1092
- CCCLII. . “**Expression Profile of TRAIL and its Receptors in Breast Cancer patients with invasive ductal carcinoma**” Vol. 5 (4), EJC Supement Elsevier, 2007.
SANLIOGLU A. D., KORCUM A. F., PEŞTERELİ H. E., ERDOĞAN G., KARAVELİ F. Ş., ŞANLIOĞLU S., SAVAŞ B., GRIFFITH T.
14th European Cancer Conference, Barcelona, Spain, 23 - 27 September 2007, pp.2136
- CCCLIII. **Expression profile of TRAIL and its receptors in breast cancer patients with invasive ductal carcinoma**
KORCUM A. F., ŞANLIOĞLU A. D., PEŞTERELİ H. E., ERDOĞAN G., KARAVELİ F. Ş., Savaş B., GRIFFITH T., ŞANLIOĞLU S.
ECCO 14 The European Cancer Conference, Barcelona, Spain, 23 - 27 September 2007, pp.225-226
- CCCLIV. **Tip 1 diyabet gelişiminde rol alan TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili ve artan apoptozis ile korelasyonu**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., BALCI M. K., Griffith T. S.
X. Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.112
- CCCLV. **Adenoviral vektörler sitotoksik etki oluşturmadan pankreatik adacıklara etkin TRAIL gen aktarımı sağlar**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., Griffith T. S.
X. Tibbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.134
- CCCLVI. **Adenovirus aracılı TRAIL transferi osteoartritli hastalardan izole edilmiş normalde apoptoza dirençli sinovyal fibroblastları yok etti**

- ŞANLIOĞLU S., ŞANLIOĞLU A. D., BİSGİN A., TERZİOĞLU M. E., TÜZÜNER S.
X. Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.153
- CCCLVII. **Tip 1 diyabet gelişiminde rol alan TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili ve artan apoptozis ile korelasyonu**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., BALCI M. K., Griffith T. S.
X. Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.112
- CCCLVIII. **Tip 1 diyabet gelişiminde rol alan TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili ve artan apoptozis ile korelasyonu**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., BALCI M. K., ÖMER A., GRIFFITH T., ŞANLIOĞLU S.
X. Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.232
- CCCLIX. **Potential therapeutic efficacy of adenovirus delivery of TRAIL for patients with prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÇİFTÇİOĞLU M. A., Griffith T. S.
X. Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.11
- CCCLX. **Potential therapeutic efficacy of adenovirus delivery of TRAIL for patients with prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÇİFTÇİOĞLU M. A., Griffith T. S.
X. Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.11
- CCCLXI. **Adenoviral vektörler sitotoksik etki oluşturmadan pankreatik adacıklara etkin TRAIL gen aktarımı sağlar**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., Griffith T. S.
X. Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 6 - 09 September 2007, pp.134
- CCCLXII. **High endogenous TRAIL expression levels in human pancreas is correlated with increased cell death**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., BALCI M. K., ÖMER A., GRIFFITH T., ŞANLIOĞLU S.
XVth Annual Congress of the European Society of Gene and Cell Therapy, Roterrdam, Netherlands, 1 - 06 August 2007, pp.1074-1075
- CCCLXIII. **Testing the efficacy of substance P fragments as anti-tumor agents.**
ŞİMŞEK E., AYDEMİR E., FIŞKİN K., KORCUM A. F., ERİN N., ŞANLIOĞLU S.
6th AFMC International Medicinal Chemistry Symposium, İstanbul, Turkey, 8 - 11 July 2007, pp.45
- CCCLXIV. **Testing the efficacy of Substance P fragments as anti-tumor agents**
ERİN N., KORCUM A. F., ŞİMŞEK E., AYDEMİR E., ŞANLIOĞLU S.
6th AFMC International Medicinal Chemistry Symposium, İstanbul, Turkey, 8 - 11 July 2007, pp.58
- CCCLXV. **Tip 1 diyabette ölümcül ligant aracılı gen tedavi modelinin moleküller etki mekanizması.**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., TERZİOĞLU M. E., BALCI M. K., SARI R., Griffith T. S.
43. Ulusal Diyabet Kongresi, Antalya, Turkey, 9 - 13 May 2007, pp.45
- CCCLXVI. **Yokluğu Tip 1 diyabetle ilişkilendirilmiş TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., BALCI M. K., Griffith T. S.
43. Ulusal Diyabet Kongresi, Antalya, Turkey, 9 - 13 May 2007, pp.54
- CCCLXVII. **Tip 1 diyabetli hastalarda kullanılacak etkin bir tedavi modelinin geliştirilmesi maksadıyla pankreatik adacıklara adenovirus aracılı TRAIL geni aktarımı**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., Griffith T. S.
43. Ulusal Diyabet Kongresi, Antalya, Turkey, 9 - 13 May 2007, pp.51
- CCCLXVIII. **Tip 1 diyabette ölümcül ligant aracılı gen tedavi modelinin moleküller etki mekanizması.**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., TERZİOĞLU M. E., BALCI M. K., SARI R., Griffith T. S.
43. Ulusal Diyabet Kongresi, Antalya, Turkey, 9 - 13 May 2007, pp.45
- CCCLXIX. **Tip 1 diyabetli hastalarda kullanılacak etkin bir tedavi modelinin geliştirilmesi maksadıyla pankreatik adacıklara adenovirus aracılı TRAIL geni aktarımı**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., Griffith T. S.
43. Ulusal Diyabet Kongresi, Antalya, Turkey, 9 - 13 May 2007, pp.51
- CCCLXX. **Yokluğu Tip 1 diyabetle ilişkilendirilmiş TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve**

- yalancı reseptörlerinin normal insan pankreasındaki sentez profili**
ŞANLIOĞLU A. D., DİRİCE E., ELPEK G. Ö., KORCUM A. F., BALCI M. K., ÖMER A., GRIFFITH T., ŞANLIOĞLU S.
43. ULUSAL DİYABET KONGRESİ, Antalya, Turkey, 9 - 13 May 2007, pp.66
- CCCLXXI. Yokluğu Tip 1 diyabetle ilişkilendirilmiş TNF-Related Apoptosis Inducing Ligand (TRAIL) ölümcül ve yalancı reseptörlerinin normal insan pankreasındaki sentez profili**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., KORCUM ŞAHİN A. F., Dirice E., ELPEK G. Ö., BALCI M. K., Griffith T. S.
43. Ulusal Diyabet Kongresi, Antalya, Turkey, 9 - 13 May 2007, pp.54
- CCCLXXII. Upnormal increase in the nuclear NF- κ B activity of the rat cavernosal tissue is correlated with diabetes related erectile dysfunction syndrome**
ŞANLIOĞLU S., USTA M. F., YOLDAŞ ÇELİKTEMİN S. B.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.213
- CCCLXXIII. A DcR2 siRNA strategy employing three different siRNA constructs in combination defeats adenovirus transferred TRAIL resistance in lung cancer cells**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., AKDIS C., aydın ç., ÖZBİLİM G., DERTSİZ L., ÖZBUDAK Ö.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.103
- CCCLXXIV. TRAIL-R4 (DcR2) receptor gene expression is correlated with high Gleason scores, PSA recurrence, and decreased survival in patients with prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., KÖKSAL İ. T., Griffith T. S.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.141
- CCCLXXV. Upnormal increase in the nuclear NF- κ B activity of the rat cavernosal tissue is correlated with diabetes related erectile dysfunction syndrome**
ŞANLIOĞLU S., USTA M. F., YOLDAŞ ÇELİKTEMİN S. B.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.213
- CCCLXXVI. Small interference RNA technology targeting DcR2 sensitized advanced prostate carcinoma cells to adenovirus delivery of TRAIL**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., KÖKSAL İ. T.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.103
- CCLXXVII. Electroporation enhances the first generation adenovirus vector transgene delivery into pancreatic islets**
ŞANLIOĞLU S., Dirice E., ŞANLIOĞLU A. D., BALCI M. K., Ömer A.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.208
- CLXXVIII. Novel gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., BİSGİN A., ULKER M., TERZİOĞLU M. E., TUZUNER S., YAZISIZ V.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.206
- CCCLXXIX. TRAIL-R4 (DcR2) receptor gene expression is correlated with high Gleason scores, PSA recurrence, and decreased survival in patients with prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., KÖKSAL İ. T., Griffith T. S.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.141
- CCCLXXX. Small interference RNA technology targeting DcR2 sensitized advanced prostate carcinoma cells to adenovirus delivery of TRAIL**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., KÖKSAL İ. T.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.103
- CCCLXXXI. Electroporation enhances the first generation adenovirus vector transgene delivery into pancreatic islets**
ŞANLIOĞLU S., Dirice E., ŞANLIOĞLU A. D., BALCI M. K., Ömer A.
XIV Annual Congress of the European Society of Gene Therapy, Atina, Greece, 9 - 12 November 2006, pp.208
- CCLXXXII. Differential expression of trail and its receptors in patients with prostate carcinoma**
Sanlioglu A. D., KOKSAL I. T., CIFTCIOGLU A., Baykara M., LULECI G., Sanlioglu S.
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006, vol.273, pp.133
- CLXXXIII. Adenovirus delivery of TRAIL effectively destroys synoviocytes of patients with rheumatoid arthritis**

- BISGIN A., Sanlioglu A. D., ULKER M., TUZUNER S., Terzioglu E., Sanlioglu S.
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006,
vol.273, pp.134
- CCLXXXIV. **Adenovirus mediated TRAIL gene delivery as a model for the treatment of patients with diabetes**
DİRİCE E., Sanlioglu A. D., OMER A., Balci M. K., Terzioglu E., Sanlioglu S.
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006,
vol.273, pp.206
- CCLXXXV. **A DCR2 siRNA approach defeats trail resistance in lung cancer cells**
AYDIN C., Sanlioglu A. D., OZBUDAK O., DERTSIZ L., OZBILIM G., AKDIS C. A., Sanlioglu S.
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006,
vol.273, pp.133
- CCLXXXVI. **Mechanism of TRAIL resistance in breast cancer cells for adenovirus mediated gene delivery**
Koksoy S., SANLIOĞLU A. D., Sanlioglu S.
Annual Meeting of the American-Association-of-Immunologists, Massachusetts, United States Of America, 12 - 16
May 2006, vol.176
- CLXXXVII. **Novel gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis.**
Abstract. P206. Athens, Greece, 2006.
Bisgin A., ŞANLIOĞLU A. D., Ulker M., YAZISIZ V., TÜZÜNER S., TERZİOĞLU M. E., ŞANLIOĞLU S.
XIV Annual Congress of the European Society of Gene Therapy,, Atina, Greece, 01 March 2006, vol.1, pp.206
- CCLXXXVIII. **DcR2 siRNA yaklaşımı A549 akciğer kanser hücrelerini adenovirus aracılı TRAIL transferine duyarlı
kilar**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydin ç., DERTSİZ L., ÖZBUDAK Ö.
IX. Ulusal Tibbi Biyoloji Kongresi, Manisa, Turkey, 24 - 27 November 2005, pp.5
- CCLXXXIX. **Adenovirus aracılı ölümcül ligand transferinin gen tedavisindeki yeri.**
ŞANLIOĞLU S.
IX. Ulusal Tibbi Biyoloji Kongresi, Manisa, Turkey, 24 - 27 November 2005, pp.19
- CCCXC. **Tip 1 diyabetli hastalar için geliştirilen pankreatik adacık transplantasyonunda adenovirus aracılı
TRAİL gen transferinin etkinliği**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K.
IX. Ulusal Tibbi Biyoloji Kongresi, Manisa, Turkey, 24 - 27 November 2005, pp.66
- CCCXCII. **İleri evre prostat karsinomada yalancı reseptör gen ekspresyonu TRAIL dirençliliğinin ortaya
çıkmasında önemli bir faktördür**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M., Griffith T. S.
IX. Ulusal Tibbi Biyoloji Kongresi, Manisa, Turkey, 24 - 27 November 2005, pp.12
- CCCXCIII. **İleri evre prostat karsinomada yalancı reseptör gen ekspresyonu TRAIL dirençliliğinin ortaya
çıkmasında önemli bir faktördür**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M., Griffith T. S.
IX. Ulusal Tibbi Biyoloji Kongresi, Manisa, Turkey, 24 - 27 November 2005, pp.12
- CCCXCIV. **Tip 1 diyabetli hastalar için geliştirilen pankreatik adacık transplantasyonunda adenovirus aracılı
TRAİL gen transferinin etkinliği**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K.
IX. Ulusal Tibbi Biyoloji Kongresi, Manisa, Turkey, 24 - 27 November 2005, pp.66
- CCCXCIV. **Adenovirus aracılı TRAIL gen transferinin romatoid artritli hastalıklardaki terapötik etkisi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., BISGIN A., ULKER M., TERZİOĞLU M. E., TÜZÜNER S.
IX. Ulusal Tibbi Biyoloji Kongresi, Manisa, Turkey, 24 - 27 November 2005, pp.41
- CCCXCIV. **A CTLA-4 EXON 1+49 A/A Genotype is linked to the clinical progression of systemic lupus
erythematosus in patients. p.076, 29 October-1 November, 2005. Prague, Czech Republic.**
Ulker M., TERZİOĞLU M. E., YAZISIZ V., ŞANLIOĞLU S.
13 th Annual Congress of the European Society of Gene Theraphy,, Prag, Czech Republic, 29 October - 01
November 2005, vol.1, pp.76
- CCCXCVI. **Sistemik Lupus Eritematosuzlu hastalarda CTLA- 4 Exon I(+49 G/A) polimorfizmi ve hastalık**

- aktivasyonuyla ilişkisi. PT.26,**
Ulker M., YAZISIZ V., KÖKSOY S., ŞANLIOĞLU S., TERZİOĞLU M. E.
Ramatoloji Kongresi 2005, Konya, Turkey, 30 September - 04 October 2005, pp.26
- CCCXCVII. A CTLA-4 exon 1+49 A/A genotype is linked to the clinical progression of systemic lupus erythematosus in patients**
ŞANLIOĞLU S., ULKER M., TERZİOĞLU M. E., YAZISIZ V.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.76
- CCCXCVIII. Adenovirus delivery of TRAIL effectively destroys synovial fibroblasts of patients with rheumatoid arthritis**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., BISGIN A., ULKER M., TERZİOĞLU M. E., TUZUNER S.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.75
- CCXCIX. Testing the efficacy of an adenovirus mediated TRAIL gene delivery for the treatment of patients with osteoarthritis**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., BISGIN A., ULKER M., TERZİOĞLU M. E., TUZUNER S.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.78
- CD. Decoy receptor gene expression as a chief mechanism to govern TRAIL resistance in advanced prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.23
- CDI. Surface TRAIL decoy receptor-4 expression constitutes a resistance to adenovirus delivery of TRAIL in MCF7 breast cancer cells**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydin ç., Dirice E., KÖKSOY S., ERİN E.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.15
- CDII. Adenovirus mediated NF-κB inhibiting strategies for the treatment of patients with type 1 diabetes**
ŞANLIOĞLU S., YOLDAŞ ÇELİKTEM Ş. B.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.88
- CDIII. Efficient adenovirus mediated TRAIL gene delivery into pancreatic islets as a model for the treatment of patients with type 1 diabetes**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.74
- CDIV. TRAIL ligand and receptor expressions are differentially upregulated in prostate carcinoma patients: a significant issue for gene therapy of advanced prostate cancer**
ŞANLIOĞLU S., CIFTÇIOĞLU A., ŞANLIOĞLU A. D., Lüleci G., KÖKSAL İ. T., BAYKARA M., BAŞSORGUN C. İ.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.22
- CDV. A DcR2 siRNA approach overcomes TRAIL resistance in A549 lung cancer cells**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydin ç., DERTSİZ L., ÖZBUDAK Ö.
13th Annual Congress of European Society of Gene Therapy, Prague, Czech Republic, 29 September - 01 October 2005, pp.172
- CDVI. The implication of adenovirus mediated death ligand gene delivery for human gene therapy**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Lüleci G., KÖKSAL İ. T., BAYKARA M.
XVIII. Ulusal İmmunoloji Kongresi, Antalya, Turkey, 27 September - 01 October 2005, pp.43
- CDVII. The implication of adenovirus mediated death ligand gene delivery for human gene therapy**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Lüleci G., KÖKSAL İ. T., BAYKARA M.

- XVIII. Ulusal İmmunoloji Kongresi, Antalya, Turkey, 27 September - 01 October 2005, pp.43
- CDVIII. **A novel death ligand mediated gene therapy approach for patients with lung cancer**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydın ç., Dirice E., DERTSİZ L., ÖZBUDAK Ö.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.162
- CDIX. **Surface TRAIL Receptor-4 expression correlates with TRAIL resistance in breast cancer cells**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydın ç., ERİN E., Dirice E., KÖKSOY S.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.164
- CDX. **Testing the efficacy of a novel adenovirus mediated TRAIL gene therapy approach for the treatment of patients with Type 1 Diabetes**
ŞANLIOĞLU S., Ömer A., ŞANLIOĞLU A. D., Dirice E., BALCI M. K., KÖKSOY S.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.160
- CDXI. **Adenovirus mediated TRAIL gene delivery as a gene therapy model for patients with advanced prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.14
- CDXII. **Adenovirus mediated IKK β KA expression sensitizes advanced prostate carcinoma cells to TRAIL-Mediated apoptosis in spite of decoy receptor gene expression**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.165
- CDXIII. **A novel gene therapy model for patients with Rheumatoid Arthritis**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., BİSGİN A., Dirice E., ULKER M., TERZİOĞLU M. E., KÖKSOY S., TÜZÜNER S.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.161
- CDXIV. **Surface TRAIL Receptor-4 expression correlates with TRAIL resistance in breast cancer cells**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydın ç., ERİN E., Dirice E., KÖKSOY S.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.164
- CDXV. **Adenovirus delivery of IKK β KA to liver improves survival in a murine model of endotoxic shock**
YOLDAŞ ÇELİKTEMEN Ş. B., ENGELHARDT J., ŞANLIOĞLU S.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.167
- CDXVI. **Adenovirus delivery of IKK β KA to liver improves survival in a murine model of endotoxic shock**
YOLDAŞ ÇELİKTEMEN Ş. B., ENGELHARDT J., ŞANLIOĞLU S.
Advances in Molecular Medicine, İstanbul, Turkey, 3 - 05 September 2005, pp.167
- CDXVII. **Current Progress in Cancer Gene Therapy**
ŞANLIOĞLU S.
XIX Ulusal Biyokimya Kongresi, Antalya, Turkey, 22 - 25 April 2005, pp.5
- CDXVIII. **Fundamental principals of Tumor Necrosis Factor-alpha gene therapy approach for patients with lung carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydın ç., BOZCUK H. Ş., TERZİOĞLU M. E.
12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 4 - 07 November 2004, pp.4
- CDXIX. **Advanced prostate cancer cells display differential NF- κ B activation pattern which is the primary determinant of TRAIL resistance**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 4 - 07 November 2004, pp.19
- CDXX. **Advanced prostate cancer cells display differential NF- κ B activation pattern which is the primary determinant of TRAIL resistance**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 4 - 07 November 2004, pp.19
- CDXXI. **Anti HIV drug PDTc genetoxic agents synergistically activate Adeno Associated Virus Type-2 endocytosis and transduction**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., ENGELHARDT J. F., BENSON P.
12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 4 - 07 November 2004, pp.56
- CDXXII. **Therapeutic effect of recombinant adenovirus mediated TRAIL gene therapy method in Lung Cancer**

- ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydın ç., Dirice E.
12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 4 - 07 November 2004, pp.22
- CDXXIII. **Resistance to Adenovirus mediated TRAIL gene therapy in breast cancer cells is eliminated by the expression of dominant negative IKK β**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Dirice E.
12th Annual Congress of European Society of Gene Therapy, Tampere, Finland, 4 - 07 November 2004, pp.20
- CDXXIV. **An in vivo model for IKK modulation of adenovirus delivery of TNF-alpha mediated gene therapy for patients with lung carcinoma**
ŞANLIOĞLU S.
British Association for Cancer Research (BACR) Conference on Stem cells and Telomerase, Famagusta, Cyprus (Kktc), 12 - 16 October 2004, pp.38
- CDXXV. **Akciğer kanserinde recombinant adenovirus aracılı TRAIL gen tedavi metodunun terapötik etkisi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., aydın ç., Dirice E.
1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 7 - 09 May 2004, pp.128
- CDXXVI. **An in vivo model for IKK modulation of adenovirus delivery of TNF-alpha mediated gene therapy for patients with lung carcinoma**
ŞANLIOĞLU S.
1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 7 - 09 May 2004, pp.135
- CDXXVII. **Hücre içi anti-apoptotik yolun bloke edilmesi meme kanserini adenovirus aracılı TRAIL gen tedavi metoduna karşı duyarlı hale getirdi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Dirice E.
1. Ulusal Klinik Pratikde Kök Hücre ve Gen Tedavisi Kongresi, İstanbul, Turkey, 7 - 09 May 2004, pp.127
- CDXXVIII. **İleri ever meme kanserinin adenovirus aracılı TRAIL gen tedavi metoduna duyarlılaştırma yöntemleri**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Dirice E.
VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Antalya, Turkey, 21 - 24 April 2004, pp.4
- CDXXIX. **Akciğer kanserinde yeni bir adenovirus aracılı TNF-alpha gen tedavi metodu**
ŞANLIOĞLU S.
VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Antalya, Turkey, 21 - 24 April 2004, pp.8
- CDXXX. **İleri ever prostat kanserinde NFkB yolunun bloke edilmesi TRAIL dirençliliğini kırar**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Antalya, Turkey, 21 - 24 April 2004, pp.27
- CDXXXI. **İleri ever prostat kanserinde NFkB yolunun bloke edilmesi TRAIL dirençliliğini kırar**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Antalya, Turkey, 21 - 24 April 2004, pp.27
- CDXXXII. **Karaciğerde adenovirus aracılı dominant negative IKK beta mutandının gen sentezi endotoksik şoktan hayatı kalma süresini arttırır.**
ŞANLIOĞLU S., ENGELHARDT J. F.
VI. Ulusal Prenatal Tanı ve Tibbi Genetik Kongresi, Antalya, Turkey, 21 - 27 April 2004, pp.47
- CDXXXIII. **Adenovirus mediated NF-kB inhibiting gene therapy for breaking down TRAIL resistance observed in advanced prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
11th Annual Congress of European Society of Gene Therapy, Edinburgh, United Kingdom, 13 - 16 November 2003, pp.234
- CDXXXIV. **Adenovirus mediated NF-kB inhibiting gene therapy for breaking down TRAIL resistance observed in advanced prostate carcinoma**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., KARACAY B., Lüleci G., KÖKSAL İ. T., BAYKARA M.
11th Annual Congress of European Society of Gene Therapy, Edinburgh, United Kingdom, 13 - 16 November 2003, pp.234
- CDXXXV. **Gene Expression of a Dominant Negative IKK-beta Mutant in the Liver Improves Survival in a Murine Model of Endotoxic Shock**

ŞANLIOĞLU S., ŞANLIOĞLU A. D., WILLIAMS C., ENGELHARDT J. F.

11th Annual Congress of European Society of Gene Therapy, Edinburgh, United Kingdom, 13 - 16 November 2003,
pp.269

- CDXXXVI. **TRAIL-Mediated Apoptosis of Neuroblastoma cells is Enhanced by Simultaneous Inhibition of the NF-kB Pathway**
ŞANLIOĞLU S., SANDLER A., KARACAY B., BONTHIUS D., Griffith T. S., PANTAZIS N. J.
Neuroscience Meeting, New Orleans, United States Of America, 8 - 12 November 2003, pp.751
- CDXXXVII. **Adenovirus aracılı TRAIL geni aktarımının prostat karsinomanın farklı evreleri üzerindeki etkinliği
ve prostat kanserli hastalarda TRAILe olan direnci kırmak için yeni gen tedavi metodlarının
geliştirilmesi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Lüleci G., KÖKSAL İ. T., BAYKARA M.
8. Ulusal Tıbbi Biyoloji Kongresi, Adana, Turkey, 14 - 17 October 2003, pp.3
- DXXXVIII. **PTENin Gleason skoru ve PSAya kıyasla prostat kanserindeki prognostik değerinin belirlenmesi.**
ŞANLIOĞLU S., CIFTCIOGLU A., ŞANLIOĞLU A. D., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., GÜLKESEN K. H.,
BAYKARA M., ÖZEŞ O. N.
8. Ulusal Tıbbi Biyoloji Kongresi, Adana, Turkey, 14 - 17 October 2003, pp.5
- CDXXXIX. **Mesane kanser gelişiminde PTENin prognostik değerinin belirlenmesi**
ŞANLIOĞLU S., CIFTCIOGLU A., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N., KARAÜZÜM S.
8. Ulusal Tıbbi Biyoloji Kongresi, Adana, Turkey, 14 - 17 October 2003, pp.4
- CDXL. **PTENin Gleason skoru ve PSAya kıyasla prostat kanserindeki prognostik değerinin belirlenmesi.**
ŞANLIOĞLU S., CIFTCIOGLU A., ŞANLIOĞLU A. D., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., GÜLKESEN K. H.,
BAYKARA M., ÖZEŞ O. N.
8. Ulusal Tıbbi Biyoloji Kongresi, Adana, Turkey, 14 - 17 October 2003, pp.5
- CDXLI. **Mesane kanser gelişiminde PTENin prognostik değerinin belirlenmesi**
ŞANLIOĞLU S., CIFTCIOGLU A., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N., KARAÜZÜM S.
8. Ulusal Tıbbi Biyoloji Kongresi, Adana, Turkey, 14 - 17 October 2003, pp.4
- CDXLII. **Gen tedavisinde güncel gelişmeler.**
ŞANLIOĞLU S., ŞANLIOĞLU A. D.
8. Ulusal Tıbbi Biyoloji Kongresi, Adana, Turkey, 14 - 17 October 2003, pp.2
- CDXLIII. **Adenovirus aracılı TRAIL geni aktarımının prostat karsinomanın farklı evreleri üzerindeki etkinliği
ve prostat kanserli hastalarda TRAILe olan direnci kırmak için yeni gen tedavi metodlarının
geliştirilmesi**
ŞANLIOĞLU S., ŞANLIOĞLU A. D., Lüleci G., KÖKSAL İ. T., BAYKARA M.
8. Ulusal Tıbbi Biyoloji Kongresi, Adana, Turkey, 14 - 17 October 2003, pp.3
- CDXLIV. **Prostat kanserli olgularda PTEN ekspresyonunun prognostic değeri**
ŞANLIOĞLU S., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N.
XV. Ulusal Kanser Kongresi, Antalya, Turkey, 23 - 27 April 2003, pp.559
- CDXLV. **PTEN ekspresyon düzeyinin mesane kanseri gelişimindeki rolü**
ŞANLIOĞLU S., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N., KARAÜZÜM S.
XV. Ulusal Kanser Kongresi, Antalya, Turkey, 23 - 27 April 2003, pp.558
- CDXLVI. **PTEN ekspresyon düzeyinin mesane kanseri gelişimindeki rolü**
ŞANLIOĞLU S., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N., KARAÜZÜM S.
XV. Ulusal Kanser Kongresi, Antalya, Turkey, 23 - 27 April 2003, pp.558
- CDXLVII. **Prostat kanserli olgularda PTEN ekspresyonunun prognostic değeri**
ŞANLIOĞLU S., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N.
XV. Ulusal Kanser Kongresi, Antalya, Turkey, 23 - 27 April 2003, pp.559
- CDXLVIII. **PTEN expression inversely correlates with high Gleason scores and serum PSA levels which are the
major prognostic indicators of the advanced prostate carcinoma**
ŞANLIOĞLU S., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N.
6th Seminar of the International Cooperative Study of Diagnostic Ultrasound and Prostate Cancer, Antalya, Turkey,
3 - 05 October 2002, pp.31

- CDLIX. **PTEN expression inversely correlates with high Gleason scores and serum PSA levels which are the major prognostic indicators of the advanced prostate carcinoma**
 ŞANLIOĞLU S., YASAR D., Dirice E., Lüleci G., KÖKSAL İ. T., BAYKARA M., ÖZEŞ O. N.
 6th Seminar of the International Cooperative Study of Diagnostic Ultrasound and Prostate Cancer, Antalya, Turkey,
 3 - 05 October 2002, pp.31
- CDL. **A new treatment modality for lung cancer; Differential regulation of Rac1 and IKK pathways sensitizes lung cancer cells to TNF mediated apoptosis**
 ŞANLIOĞLU S., Lüleci G., THOMAS K.
 9th Annual Meeting of European Society of Gene Therapy, Antalya, Turkey, 2 - 04 November 2001, pp.149
- CDLI. **Novel approaches to induce Adeno-associated virus type-2 endocytosis through synergistic activation of Rac1 and PI3K pathways**
 ŞANLIOĞLU S., ENGELHARDT J., BENSON P., RITCHIE T.
 4th Annual Meeting of American Society of Gene Therapy, Seattle, United States Of America, 30 May - 03 June 2001,
 pp.522
- CDLII. **Regulation of Adeno-Associated Virus Type-2 Endocytosis and Nuclear Trafficking by Rac1/PI3-kinase Pathways**
 ŞANLIOĞLU S., ATKINSON E., YANG J., ENGELHARDT J., BENSON P., REYNOLDS T.
 3rd Annual Meeting of American Society of Gene Therapy, Colorado, United States Of America, 31 May - 04 June
 2000, pp.348
- CDLIII. **ATM gene defect increases the efficiency of adeno-associated virus transductions**
 ŞANLIOĞLU S., ENGELHARDT J. F.
 2nd Annual Meeting of American Society for Gene Therapy, Washington Dc, United States Of America, 9 - 13 June
 1999, pp.596
- CDLIV. **UV radiation and reactive oxygen species augment rAAV transduction through NFkB independent pathways.**
 ŞANLIOĞLU S., ENGELHARDT J. F.
 Pediatric Pulmonology, Malden, United States Of America, 1 - 05 October 1998, pp.226
- CDLV. **UV radiation increases the abundance of AAV circular but not replication form intermediates**
 ŞANLIOĞLU S., ENGELHARDT J. F.
 Pediatric Pulmonology, Malden, United States Of America, 1 - 05 October 1998, pp.227
- CDLVI. **Effect of ectopic En-2 expression in Purkinje cells on development of the cerebellum**
 ŞANLIOĞLU S., OBERDICK J.
 Society for Neuroscience, Washington Dc, United States Of America, 16 - 21 November 1996, pp.121

Supported Projects

ERENDOR F., ŞANLIOĞLU S., TUBITAK Project, Lentivirus Aracılı Vazoaktif İntestinal Peptid Gen Naklinin Retinal Dejeneratif Hastalık Modelindeki Potansiyel Terapötik Etkinliği, 2019 - Continues

KESER İ., ŞANLIOĞLU A. D., Tokta Ö., Billor M., ALPER Ö., KARAÜZÜM S., YOLDAŞ ÇELİKTEKİN S. B., YAKUT UZUNER S., HANGÜL C., ÖZBUDAK İ. H., et al., Project Supported by Higher Education Institutions, Bilimsel Araştırmalarda Tıbbi Biyoloji ve Genetik Anabilim Dalının Yeri ve Önemi, 2019 - 2020

ÖZBEN TOMASI T., ŞANLIOĞLU S., ŞANLIOĞLU A. D., BİLMEN S., SÜLEYMANLAR G., ÖZDEM S., Project Supported by Higher Education Institutions, Yayın Sürekliklilik Desteği 2018, 2018 - 2019

ŞANLIOĞLU S., ERENDOR F., TUBITAK Project, Pankreasa Yönlendirilmiş Lentiviral Vektörlerle İnsülin Gen Naklinin Terapötik Etkinliğinin Diyabetik Deney Hayvan Modellerinde Belirlenmesi, 2016 - 2019

TAŞYUREK M. H., ŞANLIOĞLU S., TUBITAK Project, İnsan Glukagon Benzeri Peptid-1 (GLP-1) Taşıyan Gen Nakil Vektörlerinin Diyabetik Deney Hayvan Modelinde Terapötik Etkinliklerinin Belirlenmesi, 2012 - 2015

Metrics

Publication: 549

Citation (WoS): 2046

Citation (Scopus): 2332

H-Index (WoS): 27

H-Index (Scopus): 28